

## Neuroimaging standards for research into small vessel disease – advances since 2013

### Standards for Reporting Vascular Changes on Neuroimaging 2 (STRIVE-2)

Prof Marco Duering MD<sup>1,2</sup>, Prof Geert Jan Biessels PhD<sup>3</sup>, Prof Amy Brodtmann PhD<sup>4,5</sup>,  
Christopher Chen FRCP<sup>6</sup>, Prof Charlotte Cordonnier PhD<sup>7</sup>, Prof Frank-Erik de Leeuw PhD<sup>8</sup>,  
Prof Stéphanie Debette PhD<sup>9</sup>, Richard Frayne PhD<sup>10,11,12</sup>, Prof Eric Jouvent MD<sup>13,14</sup>,  
Prof Natalia S Rost MD<sup>15</sup>, Annemieke ter Telgte PhD<sup>16</sup>, Prof Rustam Al-Shahi Salman PhD<sup>17</sup>,  
Prof Walter H Backes PhD<sup>18</sup>, Hee-Joon Bae MD<sup>19</sup>, Rosalind Brown PhD<sup>17</sup>, Prof Hugues Chabriat MD<sup>20</sup>,  
Alberto De Luca PhD<sup>21,22</sup>, Prof Charles deCarli MD<sup>23</sup>, Anna Dewenter MSc<sup>1</sup>, Fergus N Doubal PhD<sup>17</sup>,  
Prof Michael Ewers PhD<sup>1</sup>, Thalia S Field MD<sup>24,25</sup>, Aravind Ganesh PhD<sup>26,11,27</sup>,  
Prof Steven Greenberg PhD<sup>15</sup>, Karl G Helmer PhD<sup>28,29</sup>, Saima Hilal PhD<sup>30</sup>,  
Angela C C Jochems MSc<sup>17,31</sup>, Hanna Jokinen PhD<sup>32,33</sup>, Hugo Kuijf PhD<sup>21</sup>, Bonnie Y K Lam PhD<sup>34,35,36</sup>,  
Jessica Lebenberg PhD<sup>13,14</sup>, Bradley J MacIntosh PhD<sup>37,38,39</sup>, Pauline Maillard PhD<sup>23</sup>,  
Prof Vincent C T Mok MD<sup>34,35</sup>, Prof Leonardo Pantoni MD<sup>40</sup>, Salvatore Rudilosso PhD<sup>41</sup>,  
Claudia L Satizabal PhD<sup>42,43,44</sup>, Markus D Schirmer PhD<sup>15</sup>, Prof Reinhold Schmidt MD<sup>45</sup>,  
Prof Colin Smith MD<sup>17</sup>, Julie Staals PhD<sup>46,47</sup>, Michael J Thrippleton PhD<sup>48</sup>, Susanne J van Veluw PhD<sup>15</sup>,  
Prof Prashanthi Vemuri PhD<sup>49</sup>, Prof Yilong Wang PhD<sup>50</sup>, Prof David Werring PhD<sup>51</sup>,  
Marialuisa Zedde MD<sup>52</sup>, Prof Rufus O Akinyemi PhD<sup>53</sup>, Prof Oscar H Del Brutto MD<sup>54</sup>,  
Prof Hugh S Markus MD<sup>55</sup>, Prof Yi-Cheng Zhu MD<sup>56</sup>, Prof Eric E Smith MD<sup>\*57,11</sup>,  
Prof Martin Dichgans MD<sup>\*1,58,59,60</sup>, Prof Joanna M Wardlaw MD<sup>\*17,31</sup>

<sup>1</sup>Institute for Stroke and Dementia Research (ISD), University Hospital, LMU Munich, Munich, Germany

<sup>2</sup>Medical Image Analysis Center (MIAC) and Department of Biomedical Engineering, University of Basel, Basel, Switzerland

<sup>3</sup>Department of Neurology, UMC Utrecht Brain Center, University Medical Center Utrecht, Utrecht, the Netherlands

<sup>4</sup>Cognitive Health Initiative, Central Clinical School, Monash University, Melbourne, Australia

<sup>5</sup>Florey Institute of Neuroscience and Mental Health, University of Melbourne, Melbourne, Australia

<sup>6</sup>Memory Aging and Cognition Centre, Departments of Pharmacology and Psychological Medicine, Yong Loo Lin School of Medicine, National University of Singapore, Singapore

<sup>7</sup>Univ. Lille, Inserm, CHU Lille, U1172 - LilNCog - Lille Neuroscience & Cognition, Lille, France

<sup>8</sup>Department of Neurology, Donders Center for Medical Neuroscience, Radboudumc, Nijmegen, the Netherlands

<sup>9</sup>Bordeaux Population Health Research Center, University of Bordeaux, Inserm, UMR 1219, Bordeaux, France

<sup>10</sup>Departments of Clinical Neurosciences and Radiology, University of Calgary, Calgary, Canada

<sup>11</sup>Hotchkiss Brain Institute, University of Calgary, Calgary, Canada

<sup>12</sup>Seaman Family MR Research Centre, Foothills Medical Centre, University of Calgary, Calgary, Canada

<sup>13</sup>APHP, Lariboisière Hospital, Translational Neurovascular Centre, FHU NeuroVasc, Université Paris Cité, Paris, France

<sup>14</sup>Université Paris Cité, INSERM UMR 1141 NeuroDiderot, Paris, France

<sup>15</sup>Department of Neurology, Massachusetts General Hospital, Boston, MA, USA

<sup>16</sup>VASCage – Research Centre on Vascular Ageing and Stroke, Innsbruck, Austria

<sup>17</sup>Centre for Clinical Brain Sciences, University of Edinburgh, Edinburgh, UK

<sup>18</sup>Schools for Mental Health & Neuroscience and Cardiovascular Diseases, Department of Radiology & Nuclear Medicine, Maastricht University Medical Center, Maastricht, the Netherlands

<sup>19</sup>Department of Neurology, Seoul National University College of Medicine and Cerebrovascular Disease Center, Seoul National University Bundang Hospital, Seongn-si, Republic of Korea

<sup>20</sup>Centre Neurovasculaire Translationnel - CERVCO - INSERM U1141- FHU NeuroVasc, Université Paris Cité, Paris, France

<sup>21</sup>Image Sciences Institute, University Medical Center Utrecht, Utrecht, the Netherlands

<sup>22</sup>Department of Neurology, Institute for Neurodegenerative Diseases, CHU de Bordeaux, Bordeaux, France

<sup>23</sup>Department of Neurology and Center for Neuroscience, University of California, Davis, CA, USA

<sup>24</sup>Djavad Mowafaghian Centre for Brain Health, University of British Columbia, Vancouver, Canada

<sup>25</sup>Vancouver Stroke Program, Division of Neurology, University of British Columbia, Vancouver, Canada

<sup>26</sup>Departments of Clinical Neurosciences and Community Health Sciences, University of Calgary, Calgary, Canada

<sup>27</sup>Mathison Centre for Mental Health Research & Education, University of Calgary, Calgary, Canada

<sup>28</sup>Department of Radiology, Massachusetts General Hospital and Athinoula A. Martinos Center for Biomedical Imaging, Boston, MA, USA

<sup>29</sup>Department of Radiology, Harvard Medical School, Boston, MA, USA

<sup>30</sup>Saw Swee Hock School of Public Health, National University of Singapore and National University Health System, Singapore

<sup>31</sup>UK Dementia Research Institute, University of Edinburgh, Edinburgh, UK

<sup>32</sup>Division of Neuropsychology, HUS Neurocenter, Helsinki University Hospital and University of Helsinki, Helsinki, Finland

<sup>33</sup>Department of Psychology and Logopedics, Faculty of Medicine, University of Helsinki, Helsinki, Finland

<sup>34</sup>Division of Neurology, Department of Medicine and Therapeutics, Faculty of Medicine, The Chinese University of Hong Kong, Hong Kong SAR, China

<sup>35</sup>Gerald Choa Neuroscience Institute, Margaret K.L. Cheung Research Centre for Management of Parkinsonism, Therese Pei Fong Chow Research Centre for Prevention of Dementia, Lui Che Woo Institute of Innovative Medicine, Li Ka Shing Institute of Health Science, Lau Tat-chuen Research Centre of Brain Degenerative Diseases in Chinese, The Chinese University of Hong Kong, Hong Kong SAR, China

<sup>36</sup>Nuffield Department of Clinical Neurosciences, Wellcome Centre for Integrative Neuroimaging, University of Oxford, Oxford, UK

<sup>37</sup>Sandra E Black Centre for Brain Resilience & Repair, Hurvitz Brain Sciences, Physical Sciences Platform, Sunnybrook Research Institute, Toronto, Canada

<sup>38</sup>Department of Medical Biophysics, University of Toronto, Toronto, Canada

<sup>39</sup>Computational Radiology & Artificial Intelligence unit, Radiology and Nuclear Medicine, Oslo University Hospital, Oslo, Norway

<sup>40</sup>Department of Biomedical and Clinical Science, University of Milan, Milan, Italy

<sup>41</sup>Comprehensive Stroke Center, Department of Neuroscience, Hospital Clinic and August Pi i Sunyer Biomedical Research Institute (IDIBAPS), Barcelona, Spain

<sup>42</sup>Glenn Biggs Institute for Alzheimer's and Neurodegenerative Diseases and Department of Population Health Sciences, University of Texas Health Science Center at San Antonio, San Antonio, TX, USA

<sup>43</sup>Department of Neurology, Boston University Medical Center, Boston, MA, USA

<sup>44</sup>Framingham Heart Study, Framingham, MA, USA

<sup>45</sup>Department of Neurology, Medical University Graz, Graz, Austria

<sup>46</sup>Department of Neurology, Maastricht University Medical Center, Maastricht, the Netherlands

<sup>47</sup>School for cardiovascular diseases (CARIM), Maastricht University, Maastricht, the Netherlands

<sup>48</sup>Edinburgh Imaging and Centre for Clinical Brain Sciences, University of Edinburgh, Edinburgh, UK

<sup>49</sup>Mayo Clinic, Department of Radiology, Rochester, MN, USA

<sup>50</sup>Beijing Tiantan Hospital, Capital Medical University, Beijing, China

<sup>51</sup>Stroke Research Centre, UCL Queen Square Institute of Neurology, London, UK

<sup>52</sup>Neurology Unit, Stroke Unit, Department of Neuromotor Physiology and Rehabilitation, Azienda Unità Sanitaria-IRCCS di Reggio Emilia, Reggio Emilia, Italy

<sup>53</sup>Neuroscience and Ageing Research Unit, Institute for Advanced Medical Research and Training, College of Medicine, University of Ibadan, Ibadan, Nigeria

<sup>54</sup>School of Medicine and Research Center, Universidad de Especialidades Espíritu Santo, Ecuador

<sup>55</sup>Stroke Research Group, Department of Clinical Neuroscience, University of Cambridge, Cambridge, UK

<sup>56</sup>Department of Neurology, Peking Union Medical College Hospital, Beijing, China

<sup>57</sup>Departments of Clinical Neurosciences, Community Health Science and Radiology, University of Calgary, Calgary, Canada

<sup>58</sup>Munich Cluster for Systems Neurology (SyNergy), Munich, Germany

<sup>59</sup>German Center for Neurodegenerative Diseases (DZNE, Munich), Munich, Germany

<sup>60</sup>German Centre for Cardiovascular Research (DZHK, Munich), Munich, Germany

\*These authors contributed equally to this body of work.

Correspondence to:

**Prof Joanna M Wardlaw**

Centre for Clinical Brain Sciences, University of Edinburgh,

Chancellor's Building, 49 Little France Cresc, Edinburgh, EH16 4SB, UK

E-Mail: joanna.wardlaw@ed.ac.uk

Phone: +44 141 465 9599

or

**Prof Marco Duering**

Institute for Stroke and Dementia Research (ISD)

University Hospital, LMU Munich

Feodor-Lynen-Str. 17, 81377 Munich, Germany

Email: marco.duering@med.uni-muenchen.de

Word count (main text): 5474

References: 100

Tables: 2

Figures: 3

Panels: 1

Appendix: Supplemental methods, text, tables, references, panels, and figures

## 1 **Abstract**

2 Cerebral small vessel disease (SVD) is common during ageing and may present as stroke, cognitive decline,  
3 neurobehavioural symptoms, or functional impairment. SVD frequently coexists with neurodegenerative  
4 disease, where it may exacerbate cognitive and other symptoms and affect activities of daily living. STRIVE-1  
5 categorised and standardised the diverse features of SVD visible on structural MRI. Since then, new information  
6 on these established SVD markers and novel MRI sequences or imaging features have emerged. As the impact  
7 of combined SVD imaging features becomes clearer, a key role for quantitative imaging biomarkers to  
8 determine sub-visible tissue damage, subtle abnormalities visible at high-field strength MRI, and lesion-  
9 symptom patterns, is also apparent. Together with rapidly emerging machine learning methods, these metrics  
10 may more comprehensively capture the impact of SVD on the brain, serve as intermediary outcomes in clinical  
11 trials and future routine practice. Using a similar approach to that adopted in STRIVE-1, we updated the  
12 guidance on neuroimaging of vascular changes in studies of ageing and neurodegeneration to create STRIVE-2.

## 13 Introduction

14 Cerebral small vessel disease (SVD) causes 25% of ischaemic strokes, most intracerebral haemorrhages (ICH)  
15 in older people, most vascular dementia, and is associated with mobility, gait, neurobehavioural and mood  
16 disorders.<sup>1</sup>

17 The STAndards for ReportIng Vascular changes on NEuroimaging (STRIVE-1),<sup>2</sup> published in 2013, aimed to  
18 clarify definitions of SVD features on neuroimaging; encourage consistent, unbiased use of agreed terminology;  
19 promote better understanding of the causes, symptomatology and prognosis of SVD ; and foster better  
20 prevention and treatment options. STRIVE-1 focused on recent small subcortical infarcts (RSSI), lacunes of  
21 presumed vascular origin, white matter hyperintensities of presumed vascular origin (WMH), perivascular  
22 spaces (PVS), cerebral microbleeds (CMB), and brain atrophy.

23 Since 2013, there have been significant advances in the understanding of SVD imaging features, including  
24 changes in the appearance of SVD imaging features over time, their inter-relatedness, novel SVD imaging  
25 features, and improved MRI biomarkers of brain structural and vascular functional impairments.

26 The STRIVE investigators reconvened to update the 2013 Standards and Recommendations for neuroimaging  
27 features of SVD, reflect upon and update the original terminology where necessary, and focusing on new  
28 information accruing since 2013. STRIVE-2 kept the focus on neuroimaging features and research use, not  
29 primarily on clinical features or clinical management of SVD. We thus also include emerging imaging features  
30 and key quantitative imaging methods that require standardisation in order to enable wider application in  
31 research.

## 32 Adoption of STRIVE-1 terminology

33 STRIVE-1<sup>2</sup> proposed terminology for key SVD features that described imaging characteristics and avoided  
34 assumptions about pathology, pathophysiology, and clinical associations. Optimal terms are specific, short, and  
35 related to prior usage if the prior usage was accurate, without assumptions.

36 Our systematic literature search (**appendix**, page 5) showed that STRIVE-recommended terms for WMH, PVS,  
37 and CMB have replaced more variable terms (**supplemental figure 1**). However, the preferred terms for RSSI,  
38 lacunes and brain atrophy were less well used. We reassessed these terms to determine if a better or more  
39 intuitive term might be available, adopting the same review process as in STRIVE-1, to improve standards.

## 40 **Methods**

41 See **Appendix** (page 2ff) for details. We convened 50 experts, some from STRIVE-1 plus new contributors,  
42 reflecting wide-ranging expertise, geographical location, and activity in SVD research. These divided into 10  
43 working groups with a work-group lead, provided evidence-based text and proposals, which were discussed and  
44 agreed by the whole group. We invited new external advisors.

45 We systematically searched the literature to assess harmonisation of STRIVE-1 terminologies, and new  
46 findings. We surveyed the STRIVE group on their current clinical and research acquisition protocols.<sup>2</sup> As in  
47 STRIVE-1, *terms and definitions should reflect the imaging characteristics and avoid presumptions about*  
48 *mechanisms or pathological changes, especially when these are incompletely understood, so as not to prejudice*  
49 *future studies of SVD – i.e., ‘describe what you see and not what you think you see’.*

50 We used the Delphi principle, including wide-ranging transparent discussion within workgroups, the whole  
51 group at two workshops and an anonymous online survey on contentious topics, before finalising the consensus  
52 document.<sup>2</sup> STRIVE-2 will update the STRIVE-1 entry on EQUATOR (Reporting guidelines | The EQUATOR  
53 Network, equator-network.org). To assist application and interpretation of STRIVE-2, we provide further details  
54 on unusual appearances, caveats, temporal evolution, and boundaries between features (**appendix**).  
55 STRIVE-2 builds upon and extends STRIVE-1, focussing on new knowledge of SVD while avoiding repetition  
56 of previous information. STRIVE2 should thus be read and used in conjunction with STRIVE-1.

## 57 **Search strategy and selection criteria**

58 Data were derived from a structured literature search; for methodology, search strategy and selection criteria,  
59 see **appendix** (page 5ff).



## 60 **Update on imaging features defined in STRIVE-1**

### 61 **Recent small subcortical infarct (RSSI)**

62 A recent small subcortical infarct (RSSI) describes ‘neuroimaging evidence of a recent infarction in the territory  
63 of one perforating artery, with imaging features and clinical symptoms consistent with a lesion occurring within  
64 the previous few weeks’. Among all terms proposed by STRIVE-1, RSSI is the least well applied, often called  
65 to ‘acute lacunar infarcts’ amongst other names, although authors are less likely to use the term ‘lacune’ to  
66 describe recent (and non cavitated) lesions. STRIVE-2 sought a more intuitive name, but after discussion and  
67 voting on six options, ‘recent small subcortical infarct’ remained the preferred term by a large margin. ‘Recent’  
68 (meaning ‘within the previous few weeks’, as discussed and agreed in STRIVE-1) was preferred to ‘acute’ for  
69 the same reasons as in STRIVE-1; ‘infarct’ is used cautiously since the true pathology is not fully known. The  
70 territory of a single perforating artery was operationalised in STRIVE-1 by a size criterion, a maximal axial  
71 lesion diameter of 20 mm. RSSI are associated with other SVD features, supporting an intrinsic small vessel  
72 abnormality, although not all RSSI are due to intrinsic perforating arterial disease (**figure 1A**). An RSSI is  
73 clearly linked to corresponding clinical symptoms, i.e., a focal neurological deficit. This deviates from the  
74 STRIVE principle to only use imaging characteristics, but substantially improves the clarity of this feature’s  
75 definition. The term does not apply to so-called ‘covert’ lesions, which are either asymptomatic, or associated  
76 with ‘atypical neurobehavioural symptoms/signs’, or more subtle/gradual neurological deterioration over longer  
77 time (**figure 1B**).<sup>3</sup> The nature of these covert lesions is currently less understood, and these lesions are thus  
78 currently not regarded as a core feature, but an emerging feature of SVD (see emerging features section). Non-  
79 intrinsic causes, large artery disease associations with RSSI, and acute imaging diagnosis are covered in more  
80 detail in the **appendix** (page 9f, **supplemental figure 2**).

81 Large variability in residual appearances of RSSI have emerged since STRIVE-1, including disappearance,  
82 <3 mm diameter lacune (see below), cavitation, a haemosiderin (T2\*-hypointense) rim around the lacune,<sup>4</sup> or  
83 small haemosiderin (T2\*-hypointense) ‘smudge’ with no other residual sequelae (**figure 2, supplemental table**  
84 **1, supplemental figures 3, 4, 5** for examples).<sup>5,6</sup> White matter tract degeneration around the RSSI may lead to  
85 new adjacent WMH (referred to as ‘cap’ if superior, or ‘track’ if inferior to the RSSI).<sup>7</sup> Sources of variance in  
86 end-appearances are unclear but include initial lesion size, tissue injury, inflammation, comorbidities, location,  
87 microcirculatory variations, or individual vulnerabilities.<sup>2,6,8</sup>

## 88 **Lacune (of presumed vascular origin)**

89 STRIVE-1 defined the ‘lacune of presumed vascular origin’ as a round or ovoid, subcortical, fluid-filled (CSF-  
90 like) cavity that can arise from several causes.<sup>2</sup> Lacunes may be larger in the centrum semiovale and basal  
91 ganglia than elsewhere.<sup>9</sup> The size limits were defined as 3–15 mm (axial plane); however it is now clear that  
92 lacunes <3 mm can be the end result of an RSSI (**figure 2, supplemental figure 3**),<sup>10</sup> while occasional PVS are  
93 >3 mm diameter. Lacunes resulting from an RSSI may lack a T2-hyperintense rim. Therefore, perfect  
94 differentiation of lacunes from PVS is not possible by size or rim alone and may consider shape, co-located  
95 PVS, surrounding tissue signal, etc. (**supplemental table 1**).<sup>11</sup>

96 Use of the term ‘lacune’ remains variable (**supplemental figure 1**); however, we have not identified a better  
97 term. We encourage adoption of ‘lacune’, restricting its use to cavitated lesions and adding ‘of presumed  
98 vascular origin’ when there is reasonable certainty that it followed a vascular insult. In general, ‘lacune’ should  
99 not be linked with ‘infarct’ unless certain that it results from a small subcortical infarct, since lacunes may also  
100 result from haemorrhages,<sup>2</sup> appear *de novo* in normal tissue, or within or at edges<sup>12</sup> of WMH.

101 A lacune at least doubles the future risk of stroke in persons without stroke,<sup>13</sup> and after stroke, lacunes increase  
102 the risk of poor long-term outcomes.<sup>14,15</sup>

103 Lacunes are assessed visually on T1-, T2-weighted and fluid-attenuated inversion recovery (FLAIR) images,  
104 including their number and location; cavity volume can be used, with automatic methods in development;  
105 incident lacune detection requires strict imaging criteria and validated methods.<sup>16</sup>

## 106 **White matter hyperintensity (of presumed vascular origin) (WMH)**

107 WMH, the most studied SVD feature, are hyperintense on T2-weighted (preferably FLAIR) MRI sequences,  
108 typically symmetrical between hemispheres.<sup>2</sup> The term ‘WMH of presumed vascular origin’ proposed in  
109 STRIVE-1, has been widely adopted, should be encouraged (avoiding terms such as ‘ischaemic WMH’,  
110 **supplemental panel 1**). The term ‘subcortical hyperintensities’ to describe lesions in the deep grey matter or  
111 brainstem remains useful.

112 WMH associate with future risk of stroke, stroke severity, cognitive decline, and death,<sup>13,17</sup> dependency,  
113 impaired gait, and neuropsychiatric symptoms,<sup>18</sup> and affect all main cognitive domains including memory.<sup>19,20</sup>

114 WMH generally increase with age and time but amounts reported in ‘healthy populations’ by age vary  
115 considerably for reasons that are, as yet, not fully understood, which therefore currently precludes the provision  
116 of reliable normative age-stratified WMH data.<sup>13,21</sup>

117 WMH indicate areas of tissue damage that extend into apparently-normal surrounding tissue,<sup>22</sup> detectable by  
118 quantitative imaging (see below). WMH may also decrease,<sup>21</sup> perhaps reflecting resolution of excess interstitial  
119 fluid before permanent damage has occurred.<sup>23</sup>

120 WMH are associated with impaired CVR,<sup>24</sup> increased BBB permeability,<sup>1</sup> increased vascular pulsatility,<sup>25</sup>  
121 venous collagenosis,<sup>26</sup> reduced resting cerebral blood flow in cross-sectional studies but the longitudinal  
122 relationship between WMH and CBF remains unclear.<sup>27</sup>

123 Although many semi-automated and automated methods are available to assess WMH, their reproducibility and  
124 comparability still lack in-depth characterisation (**supplemental table 1**).<sup>28</sup> Deep learning-based algorithms<sup>29</sup>  
125 are in development, but these still require validation (see below). Thus, well-validated visual scores, described  
126 in STRIVE-1 and HARNESS,<sup>2,30</sup> remain useful.

### 127 **Perivascular space (PVS)**

128 PVS are fluid-filled round/ovoid or linear spaces, following typical courses of small perforating vessels in white  
129 or deep grey matter.<sup>2,31</sup> STRIVE-1 proposed the term ‘perivascular space’ to refer to PVS visible on MRI  
130 (without the adjective ‘enlarged’) which has been widely adopted (**supplemental figure 1**). On brain MRI, PVS  
131 signal intensity is similar to CSF. Unless located within a WMH, there is typically no T2-hyperintense rim. PVS  
132 are usually <3 mm maximum axial diameter (see lacunes and **supplemental table 1**).<sup>32</sup> They are most  
133 prominent in the basal ganglia and centrum semiovale, but should not be confused with solitary developmental  
134 perivascular invaginations found in the inferior basal ganglia. T2-weighted and susceptibility-weighted  
135 sequences,<sup>33</sup> and 7T MRI<sup>34</sup> showed that MRI-visible PVS are predominantly periarteriolar.

136 PVS increase in number with age and vascular risk factors,<sup>35</sup> are highly heritable,<sup>36</sup> and associations vary with  
137 location (**supplemental table 1**), so underlying pathophysiologies may differ by anatomical distribution.<sup>31,37</sup> In  
138 the Boston 2.0 diagnostic criteria, a high burden of centrum semiovale PVS in combination with a single strictly  
139 lobar haemorrhagic feature (intracerebral haemorrhage, cerebral microbleed or cortical superficial siderosis)  
140 indicates probable cerebral amyloid angiopathy (CAA).<sup>37</sup> While a few PVS may be physiological, in a wide age  
141 range,<sup>38</sup> a large PVS burden is associated with common neurological diseases (stroke,<sup>13,31,35</sup> CAA<sup>37</sup>, Alzheimer’s  
142 disease<sup>35</sup>). PVS may occur on brain MRI earlier than lacunes, or CMB,<sup>31</sup> and precede WMH.<sup>39</sup> PVS may reflect  
143 impaired brain fluid and waste clearance,<sup>31</sup> potentially during sleep.<sup>40</sup>

144 PVS are quantified with visual rating scales (**supplemental table 1**)<sup>41</sup> which are practical. Computational  
145 methods to quantify several PVS parameters are now available<sup>42</sup> (**supplemental table 1**), which show increased

146 sensitivity for associations with WMH, retinal vessel diameters (smaller arterioles, wider venules, a proxy for  
147 cerebral small perforating arterioles and venules), or genetic variants (reflecting relevant vascular dysfunction  
148 mechanisms).<sup>42,43</sup> High-resolution T2-weighted images are recommended for best (most sensitive) PVS  
149 detection, but T1-weighted images may also be used.

## 150 **Cerebral microbleed (CMB)**

151 CMB were defined in STRIVE-1 as small, generally 2–5 mm diameter, lesions of low signal on MRI T2\* or  
152 susceptibility-weighted sequences. The original STRIVE<sup>2</sup> term ‘cerebral microbleed’ has been widely adopted.  
153 MRI-guided neuropathological examinations have confirmed that most CMB correspond to microbleeds.<sup>44</sup>  
154 CMB can be found in different anatomical locations, typically cortical grey matter and juxtacortical white  
155 matter in CAA, or deep brain structures in arteriolosclerosis (deep grey and white matter, brainstem), but  
156 regions/pathologies overlap and may share pathophysiological mechanisms: vessel wall thickening,  
157 remodelling, and BBB dysfunction may be triggered by amyloid accumulation, arteriolosclerotic vasculopathy,  
158 or both.<sup>45</sup> Strictly lobar CMB in older patients have good diagnostic accuracy for CAA,<sup>37</sup> but other pathologies  
159 occur.<sup>45,46</sup> Mixed deep-lobar CMB probably reflect arteriolosclerosis.<sup>47</sup>  
160 The Microbleeds International Collaborative Network (MICON) scores may predict risks of ICH and ischaemic  
161 stroke during antithrombotic therapy for secondary stroke prevention,<sup>48</sup> but absolute risks of recurrent ischaemic  
162 stroke exceed that of ICH, suggesting that CMB should not influence use of antiplatelet or anticoagulant drugs  
163 in secondary prevention. Limited randomised trial data also suggest that CMB do not modify effects of  
164 antithrombotic therapy on CMB formation<sup>49</sup> or clinical outcomes,<sup>50,51</sup> but more trials are needed. In CAA, the  
165 independent contribution of CMB to predict future lobar haemorrhage is limited once cortical superficial  
166 siderosis is also taken into account.<sup>52</sup>  
167 CMB are assessed using visual rating.<sup>2</sup> They are challenging to detect computationally (small size, sparse,  
168 numerous “mimics” including blood vessels, mineralisation, cysticerci in relevant countries). CT can help  
169 differentiate true CMB from calcified cysticercus<sup>53</sup> and other mimics. Computational methods in development  
170 require validation.<sup>54</sup>

### 171 **Cortical superficial siderosis (cSS)**

172 cSS as defined in STRIVE-1 describes neuroimaging evidence of chronic blood products in or overlying the  
173 superficial cortex.

174 cSS may follow convexity subarachnoid haemorrhage, superficial cortical bleeding from vascular  
175 malformations, haemorrhagic transformation of infarcts, or trauma. Most cSS in older patients results from  
176 convexity subarachnoid haemorrhage from advanced leptomeningeal vessel CAA,<sup>55</sup> sometimes with secondary  
177 cortical ischaemic injury.

178 T2\*-weighted gradient echo or other blood-sensitive sequences show cSS as a linear hypointensity over the  
179 cortex. cSS (also cerebellar<sup>56</sup>) is an accurate diagnostic biomarker of advanced CAA in the appropriate clinical  
180 setting and thus included in the Boston Criteria 2.0.<sup>37</sup>

181 Transient focal neurological episodes, observed in patients with CAA and acute convexity SAH or cSS (and  
182 occasionally a CMB), are most often unilateral, recurrent, stereotyped, spreading somatosensory disturbances,  
183 correlating anatomically between clinical presentation and convexity SAH, cSS (or occasionally a CMB)  
184 location.<sup>57</sup>

185 cSS is a strong predictor of future clinical events in CAA, e.g., risk of future ICH, functional decline, and post-  
186 ICH dementia.<sup>52</sup>

### 187 **Intracerebral haemorrhage (ICH) and other haemorrhagic markers**

188 ICH is due to SVD in 85% of cases. STRIVE-1 recommended the consensus term ‘spontaneous ICH presumed  
189 due to SVD’, replacing ‘primary ICH’, because ‘primary’ is poorly defined and to avoid discouraging  
190 determination of ICH causes.

191 ICH due to SVD includes perforating artery (arteriolosclerotic) vasculopathy and CAA. CAA is associated with  
192 lobar ICH, and scoring instruments that improve and standardise the classification of deep vs. lobar ICH, such  
193 as Cerebral Haemorrhage Anatomical RaTing inStrument (CHARTS, validated for CT and MRI), may thus  
194 support the identification of patients at higher risk of CAA.<sup>58</sup> The Edinburgh CAA criteria using two CT-based  
195 biomarkers (subarachnoid extension and “finger-like projections” of the ICH) and *APOE* genotype may help  
196 diagnose CAA-associated ICH in the acute stage when MRI may not be available, or locations where MRI  
197 availability is limited.<sup>59</sup> The Edinburgh CT and Boston MRI CAA criteria have reasonable correspondence in  
198 acute ICH due to sporadic or hereditary CAA.

## 199 **Brain atrophy**

200 STRIVE-1 defined ‘brain atrophy’ as ‘lower brain volume that is not related to a specific macroscopic focal  
201 injury such as trauma or infarction’. Ideally, brain atrophy refers to reduction in brain volume between several  
202 assessments; cross-sectionally, its definition requires a reference (e.g., intracranial volume), validated scales,  
203 local or global computational norms. We prefer ‘brain atrophy’ to ‘brain volume’ when referring to cSVD-  
204 related brain volume loss.

205 Brain atrophy is not a specific marker of SVD, and concomitant neurodegenerative disease can be a major  
206 contributor. Still, brain atrophy clearly occurs in SVD and has shown value for prognosis and monitoring. Since  
207 STRIVE-1, interest in brain atrophy in SVD has increased, with three times more publications in 2014-2021 as  
208 in the seven years preceding STRIVE-1. Both subcortical (e.g., increased ventricular volume) and cortical  
209 (thinning, sulcal widening) atrophy can result from SVD.<sup>60</sup> Potential mechanisms include secondary tract and  
210 focal cortical loss,<sup>61</sup> and possibly accumulation of smaller lesions, e.g., cortical microinfarcts.<sup>62</sup> Regional  
211 atrophy in SVD, including hippocampal atrophy, overlaps with those of other degenerative processes, including  
212 Alzheimer’s disease, but spatial patterns of brain atrophy in SVD remain to be clarified.<sup>63,64</sup> Since brain atrophy  
213 is not specific to SVD, co-occurring pathologies should be considered.

214 Brain atrophy measurement varies considerably, with increasing use of automated methods;<sup>63</sup> visual scales  
215 remain useful. Focal macroscopic (including vascular) lesions may confound brain atrophy measurement, with  
216 no agreement on how to handle focal lesions.<sup>63</sup> Cortical thickness measurements require extensive post-  
217 processing, which is error-prone with extensive SVD features,<sup>65</sup> also due to SVD effects on grey/white matter  
218 contrast.<sup>66</sup> To improve consistency and avoid post-processing issues, quantitative measures of brain atrophy  
219 should be postponed until any acute lesion is MRI-stable. Processing large datasets of patients with severe SVD  
220 should be performed with specific quality control procedures (**tables 1, 2**).

## 221 **Context, terminology, and definitions of imaging features since STRIVE-1**

### 222 **Summary SVD score**

#### 223 *Context*

224 A challenge set in STRIVE-1 was to develop an imaging scale summarising SVD burden. Major drivers were to  
225 predict outcomes, and improve participant selection/stratification for trials.

226 Several scores are now available using visual rating, mostly for MRI.<sup>67</sup> One of the first, most widely used, the  
227 ‘total SVD score’,<sup>68</sup> includes WMH, lacunes, PVS, and CMB, and has good construct validity.<sup>69,70</sup> Further  
228 scales include modifications of the ‘total SVD score’, some specific for CAA,<sup>71</sup> or adapted for CT.<sup>15</sup>

229 Our consensus was that these scales are still being developed, with more work required to attain full  
230 generalisability. A summary SVD score may aid statistics or help in clinics, but the true advantage of a  
231 combined score over individual features, and the most useful situations, remain unclear.

#### 232 *Terminology*

233 We found 1755 abstracts: 748 examined multivariable SVD markers, 198 different combinations of individual  
234 SVD markers. The commonest terms were: “cerebral small vessel disease (CSVD)” (n=73), “CSVD markers”  
235 (n=34), “CSVD burden” (n=26), with 29 papers using the additional qualifier “total”.<sup>15,68,70</sup> Forty-nine papers  
236 combined SVD markers with Alzheimer’s disease-related measures including amyloid and tau burden, while 30  
237 combined SVD measures with brain atrophy (e.g., “brain health index”).<sup>72</sup>

238 We propose the term ‘*summary SVD score*’, avoiding the words “total,” as no truly complete score exists *per se*,  
239 avoiding “burden” or “load,” to avoid emotive implications.

#### 240 *Definitions*

241 We define a summary SVD score as ‘any grouping of accepted SVD markers into a single index, score, or  
242 unitary construct’. We endorse the inclusion of markers previously defined in STRIVE-1. For between studies’  
243 comparisons, we encourage the use of validated scales and quantification tools (e.g.,<sup>70</sup>). However, we emphasise  
244 the importance of incorporating new imaging markers and methods as they arise. Including automated measures  
245 to estimate WMH volume, lacunes, PVS, CMB, or diffusion metrics, appear promising<sup>19</sup> but require validation.

246 We discussed including clinical and functional metrics into SVD scores, but agreed to focus on neuroimaging  
247 markers, due to large between-study variation in non-imaging variables.

248 For reporting, we recommend referencing a validated score, and importantly, noting any adaptations. Scores  
249 incorporating simple qualitative visual ratings are intuitive and clinically useful. Incorporating quantitative  
250 measures may provide more sensitivity but may not be tenable outside research. New scores require careful  
251 validation and testing in diverse populations, which needs to be tailored to the intended use of a new score, e.g.,  
252 as a prognostic marker.

### 253 **Cortical cerebral microinfarct (CMI)**

#### 254 *Context*

255 CMI were first described as ‘small ischemic lesions invisible to the naked eye on gross pathology’.<sup>62</sup> They are  
256 frequently observed on microscopic neuropathological examination, predominantly in cortex, and considered the  
257 most widespread form of infarction in the ageing human brain, found in 16–42% of individuals at autopsy.<sup>62</sup>  
258 CMI are not specific for SVD but also occur as a result of microembolism from cardiac or arterial sources. Since  
259 STRIVE-1, consensus rating criteria for microinfarcts during life have been proposed, aided by ultra-high field  
260 MRI and histopathology.<sup>62</sup> CMI are associated with cognitive decline.<sup>62</sup> Larger cortical CMI (0.5–4 mm) can be  
261 detected using conventional MRI, including 3D-T1-weighted and FLAIR sequences,<sup>62</sup> and as hyperintense  
262 lesions on diffusion-weighted imaging (DWI) when recent<sup>73</sup> (see below). Ultra-high field MRI increases the  
263 sensitivity of CMI detection to smaller lesions, but still detects only a fraction of lesions seen on  
264 neuropathology.

#### 265 *Terminology*

266 We screened 64 abstracts, identifying ‘cortical cerebral microinfarct’, ‘cortical microinfarction’, ‘cerebral  
267 microinfarct’, and ‘chronic microinfarct’. We propose the consensus term ‘cortical cerebral microinfarct’  
268 (cortical CMI).<sup>62</sup>

#### 269 *Definitions*

270 CMI detection is limited to cortical grey matter since CMI cannot be discriminated from WMH and PVS.<sup>62</sup> Old  
271 CMI appear T1-hypointense, T2/FLAIR-hyperintense and T2\*-isointense, and typically wedge-shaped. Based  
272 on sparse MRI-neuropathology comparisons,<sup>71</sup> CMI have been defined operationally as an upper size limit of



273 4 mm,<sup>62</sup> differing from neuropathologically-defined microinfarcts as smaller microscopic lesions are below the  
274 resolution of current MRI.

275 *Future directions*

276 Define upper size limits, develop robust criteria to detect subcortical and cerebellar CMI, and improve  
277 recognition of CMI on MRI when subacute.<sup>73</sup>

## 278 **Emerging feature**

### 279 **Incidental DWI+ lesion**

#### 280 *Context*

281 Diffusion-weighted imaging-positive (DWI+) small subcortical and tiny cortical lesions, mostly covert (without  
282 accompanying focal neurological deficit), are increasingly recognised.<sup>10</sup> They overlap with RSSIs when  
283 subcortical (**figure 1, 2**), and with recent CMI when <5 mm in cortex. They may disappear, evolve into a WMH,  
284 lacune, or old CMI (**figure 2, supplemental figure 3**), thus partly accounting for SVD progression. They are  
285 commonest in severe SVD (e.g., CADASIL, ICH), supporting an underlying intrinsic small vessel abnormality.  
286 However, like RSSI, they may also result from cardiac or arterial embolism or altered hemodynamics such as  
287 blood pressure drops (**appendix, page 8f**).

#### 288 *Terminology*

289 Commonly-used terms include acute incidental infarct, DWI or DWI-positive lesion, DWI hyperintensity,  
290 covert brain infarct, etc. Since their origin, nature, and clinical significance is unclear, following much  
291 discussion and voting, we propose the consensus term ‘incidental diffusion-weighted imaging-positive (DWI+)  
292 lesion’ for incidentally detected DWI-hyperintense lesions with an axial plane diameter  $\leq 20$  mm. Incidental  
293 detection typically refers to a lesion on an MRI scan performed in the absence of a new focal neurological  
294 deficit, or where the lesion location is unrelated to any recent symptoms.

#### 295 *Definitions*

296 Incidental DWI+ lesions appear as small hyperintense lesions on DWI, with a corresponding hypointense or  
297 isointense signal on ADC maps. Note, these lesions can also be seen as hyperintense on FLAIR or T2-weighted  
298 MRI and/or hypointense on T1-weighted MRI. An incidental DWI+ lesion accompanied by a hyperintense T1  
299 signal, suggests an acute bleeding element (haemorrhagic transformation of an infarct or primary haemorrhage).  
300 DWI must thus be used in context with other core sequences. Vice versa, other incidental lesions (e.g., lacunes  
301 or WMH) could have been DWI+ if scanned timeously. As such, increased use of DWI could highlight recent  
302 covert lesions and should be encouraged.  
303 Assessment of incidental DWI+ lesions is currently visual, computational methods are under development.

304 *Future Directions*

305 Research on this feature was very active in recent years. The STRIVE-2 group consensus was that research is  
306 still needed to address the unknowns in regard to aetiology, pathology, clinical relevance of incidental DWI+  
307 lesions, relation to symptoms and the overlap with RSSI before this feature can advance to an established SVD  
308 marker.

## 309 **Quantitative imaging markers of brain structure and function**

### 310 **Structural quantitative imaging markers of SVD brain damage**

#### 311 *Context*

312 Several quantitative imaging methods may characterise imaging features of SVD (**table 1** proposes acquisition  
313 standards).

#### 314 *Diffusion Imaging*

315 Diffusion imaging, an umbrella term, encompasses image acquisition and processing/modelling. Simple DWI is  
316 used to detect acute ischemic lesions, multi-directional DWI acquisition together with diffusion modelling helps  
317 characterise tissue microstructure. Diffusion tensor imaging (DTI) is one model capturing magnitude and spatial  
318 anisotropy of water diffusion.<sup>74</sup> Techniques like ‘Peak width of Skeletonised Mean Diffusivity’ (PSMD) may  
319 detect associations with clinical deficits in SVD better than conventional markers.<sup>75</sup> Free water fraction,  
320 calculated using a bi-tensor model, shows similar potential.<sup>76,77</sup> Diffusion metrics can be derived automatically  
321 and work in multi-site studies.<sup>75</sup> Tractography and structural connectomics have yet to demonstrate benefit over  
322 simpler diffusion metrics in SVD.<sup>78</sup>

323 Diffusion imaging depend on acquisition choices, field strength and scanner manufacturer. Such information  
324 should always be reported.

325 While sensitive to SVD brain damage, diffusion metrics lack specificity. At least in memory clinic patients the  
326 effect of SVD seems to far exceed the effect of Alzheimer’s disease on diffusion imaging.<sup>79</sup> Analysis on the  
327 fibre-population level within voxels (“fixel-based analysis”) might further improve specificity.<sup>80</sup> We endorse  
328 that diffusion alterations are reported objectively (see **supplemental panel 2** for recommended terms), avoiding  
329 assumptions about specific pathological processes.

#### 330 *Brain tissue susceptibility mapping*

331 Altered tissue susceptibility can reflect iron deposition,<sup>2</sup> or other mineralization,<sup>81</sup> which is associated with  
332 multiple brain pathologies, including vascular and Alzheimer’s disease.<sup>82</sup> Currently established measurement  
333 methods, such as T2\*-weighted and susceptibility-weighted imaging, are semiquantitative. Quantitative

334 techniques, such as R2\* relaxometry and quantitative susceptibility mapping (QSM), are promising (**appendix,**  
335 page 9).<sup>83</sup>

### 336 *Future directions*

337 Research is needed to determine the added value of diffusion or quantitative measures beyond conventional  
338 MRI.

## 339 **Markers of cerebrovascular function in SVD**

### 340 *Context*

341 SVD features addressed hitherto primarily concern tissue changes consequent upon disease originating in the  
342 vasculature. Markers of brain vascular *function* provide complementary, reliable measures of alterations in SVD  
343 (**supplemental table 2**).

### 344 *Perfusion and flow imaging*

345 Tissue perfusion is the volume of blood delivered to a unit mass of tissue per minute (cerebral blood flow,  
346 CBF), while change in tissue perfusion to a stimulus is cerebrovascular reactivity, CVR. Dynamic susceptibility  
347 contrast (DSC) MRI for static perfusion imaging and dynamic contrast-enhanced (DCE) MRI for blood-brain  
348 barrier imaging use injection of exogenous contrast to measure CBF or blood-brain barrier (BBB) function;<sup>84</sup>  
349 while arterial spin-labelling MRI<sup>85</sup> uses magnetic labelling of blood for static perfusion imaging (**supplemental**  
350 **table 2**).

351 Cross-sectionally, lower CBF associates with more WMH, CBF is lower in WMH than normal-appearing white  
352 matter,<sup>27</sup> and CVR is reduced in WMH,<sup>86</sup> but longitudinal studies are sparse.<sup>27</sup>

353 Phase contrast MRI (and duplex ultrasound) can assess blood flow velocities and pulsatility in large cranial  
354 arteries and sinuses, estimate total cerebral blood supply, and whole brain CBF. Pulsatility reflects vascular  
355 ‘stiffness’ at the measurement point, but also cardiac output, upstream and downstream vascular and tissue  
356 compliance. While numerous studies show increased vascular pulsatility in SVD cross-sectionally,  
357 longitudinally, worsening SVD may predate pulsatility increase.<sup>87</sup>

358 *Blood-brain barrier imaging*

359 Evidence since 2013 indicates that subtle BBB dysfunction is an early pathophysiologic mechanism of SVD,  
360 although is not specific. Recent MRI techniques measure BBB dysfunction through leakage of a gadolinium-  
361 based contrast agent from vessels and modelling its distribution over time. Dedicated complex methods,  
362 necessary due to the low contrast agent leakage, have demonstrated subtle BBB leakage associated with WMH,  
363 cognitive impairment, regional hypoperfusion, and increased tissue diffusivity reflecting tissue degeneration.<sup>88</sup>

## 364 **Standards for imaging and analysing SVD**

### 365 **Image acquisition**

366 MRI acquisition approaches, preferred to CT in SVD, are summarised in **table 1**, including findings from our  
367 survey among STRIVE-2 members. Several consortia have proposed standardised image acquisition  
368 protocols.<sup>89,90</sup>

369 MRI acquisition at 3T has supplanted 1.5T imaging. Higher field strengths improve visualization of CMI<sup>62</sup> and  
370 perforating arteries,<sup>91</sup> especially at 7T,<sup>92</sup> but availability remains limited.

371 Three dimensional (3D) or volumetric MR acquisition are widely used in research, and increasingly in clinical  
372 practice. Isotropic 1-mm voxels are now common spatial resolution for structural imaging and important for  
373 quantitative analyses. Innovative multislice/multiband imaging methods have decreased acquisition times and  
374 improved resolution of many 2D methods.

375 The imaging acquisition core clinical protocol for SVD remains focused on T1-weighted, T2-weighted, FLAIR,  
376 diffusion, and susceptibility imaging.

### 377 **Image analysis**

378 There have been substantial advances in computational image analysis for all SVD lesion types, individually  
379 and in combination. International consortia such as HARNES<sup>30</sup> and Mark VCID<sup>90</sup> have proposed frameworks  
380 for implementing image analysis tools that cover technical (scan-rescan repeatability, inter-scanner  
381 reproducibility) and clinical (proof-of-principle, proof-of-effectiveness) validation, with systematic validation  
382 efforts ongoing.<sup>75,90</sup>

#### 383 *Technical validation of imaging biomarker candidates*

384 For almost all feature types, some (semi)automatic image analysis methods are available. Several (**table 2,**  
385 **supplemental table 1**) demonstrate good reliability in limited settings but not yet in multiple sites or acquisition  
386 protocols. True technical validation requires test-retest (scan-rescan) repeatability, inter-site reproducibility  
387 across different scanners, and inter-rater reliability among analysts at participating sites.<sup>75</sup>

388 Some datasets with ‘ground-truth’ annotation are available for WMH,<sup>93</sup> lacunes, PVS, and CMB, to aid  
389 algorithm development and validation. Extensive testing is needed to determine the performance in large  
390 datasets with full spectra of SVD.

#### 391 *Application of machine learning / artificial intelligence (AI) methods*

392 Machine learning tools should improve SVD quantification, but availability of appropriately annotated datasets,  
393 ability to handle real-life image acquisition/quality variability, and wide range of pathophysiological variations  
394 remain challenging. Linking AI quantification of SVD markers to functional and cognitive outcomes,<sup>94</sup> and  
395 enabling deeper insights into impacts of SVD on stroke,<sup>95</sup> are ongoing.

#### 396 *SVD measures in clinical trials*

397 SVD features have been used as outcome measures in clinical trials<sup>96</sup> with some recent success (INFINITY<sup>97</sup>  
398 and SPRINT-MIND<sup>98</sup> substudies found slight reductions in WMH progression with intensive blood pressure  
399 reduction), although many trials using SVD features as outcomes were neutral.

400 Potential advantages of imaging outcomes include reduced sample size and biological relevance. Increased  
401 statistical power for longitudinal change compared with some clinical endpoints has been shown for WMH  
402 volume and diffusion metrics, such as PSMD<sup>96</sup> in observational studies, although some recent clinical measures  
403 (e.g., 7-level ordinal cognitive status score) are promising. Limitations of imaging outcomes include missing  
404 data, slow recruitment, increased trial costs, reduced generalisability, and (unless fully validated as surrogate  
405 endpoint) SVD features cannot replace clinical outcomes.<sup>3</sup> Optimal outcomes for clinical trials in SVD remain  
406 to be determined.

407 Since SVD burden is a strong outcome predictor, randomisation should be balanced on baseline SVD severity in  
408 clinical trials by stratifying on the SVD feature of interest plus other demographic/prognostic variables. This is  
409 particularly important if *change in an SVD feature* is a trial outcome.

410 Systematic frameworks have been proposed SVD imaging features for use in clinical trials, such as the  
411 HARNESS and FINESSE initiatives, to which the interested reader is referred for more information.<sup>30,96</sup>

#### 412 **Reporting standards for vascular findings on neuroimaging**

413 We updated the reporting standards established in STRIVE-1, and available on the EQUATOR Network. These  
414 are summarised in **supplemental panel 3**. We encourage investigators to use the proposed terms and definitions



415 in future studies. Adherence to the proposed reporting guidelines will increase comparability of future studies,  
416 thus facilitating meta-analyses and large-scale data analyses.

## 417 **Future developments and challenges**

418 Continually emerging SVD markers and methods may help differentiate between, or quantify, SVD and other  
419 pathologies in mixed disease, allowing faster or more consistent estimation of SVD severity, and change over  
420 time. Immediate future objectives (**supplemental panel 4**) are to differentiate RSSI due to intrinsic small vessel  
421 from non-intrinsic causes, determine the intrinsic small vessel pathology causing RSSI and DWI+ SVD features,  
422 identify the pathology that causes SVD (e.g., WMH) more gradually, determine risk factors for secondary brain  
423 damage from SVD features, and interventions to prevent, delay (or even reverse) SVD progression. Studies in  
424 low- and middle-income countries where SVD is common can facilitate our understanding of pathology and  
425 disease modifiers,<sup>99</sup> including genetic risk factors.<sup>100</sup>

426 Sophisticated imaging can facilitate pathophysiological and clinical insight, but has costs: it is not widely  
427 available; increases scan times; which may affect patient comfort, compliance or willingness to participate; has  
428 more missing data; and restricted generalisability. Studies that require imaging should balance pragmatism  
429 against perfectionism. New methods should demonstrate a clear benefit over existing markers for the intended  
430 use.

## 431 **Conclusions**

432 The steady evolution of knowledge in 10 years since STRIVE-1 has identified new SVD features, structural and  
433 functional biomarkers, accelerating understanding of SVD pathophysiology and vascular causes of  
434 neurodegeneration, bringing opportunities for prevention and treatment ever closer. We encourage use of these  
435 standards in studies of SVD and in neurodegenerative diseases, including where SVD may co-exist with several  
436 other common pathologies. They will help translate new findings into clinical practice. The challenge is to  
437 remain anchored in careful methods to ensure that truly relevant and informative findings are widely used in  
438 research and clinical practice.

439

440 These standards arose from consensus amongst many experts using rigorous methods. While the evidence base  
441 has advanced since 2013, some recommendations rely on sparse evidence in this rapidly advancing field. We  
442 did not include some very recently-described features or topics in STRIVE-2, since they are too recent, or the  
443 evidence-base for SVD is still very limited (e.g. amyloid or tau Positron Emission Tomography imaging).  
444 However, the field is moving ever-faster, and common pathologies frequently co-occur and likely interact  
445 emphasising the need for more research at these disease interfaces. More work is critical to strengthen the  
446 evidence, and bridge gaps in understanding of SVD pathophysiology. Promoting studies in less well-researched  
447 populations and regions will provide more representative and complete understanding of SVD.

**448 Contributors**

449 All authors contributed to the manuscript through attendance at the two virtual workshops, participation in  
450 specific workgroups, writing and editing the manuscript, and providing approval for final submission. JMW,  
451 MDi, ESS and MDu coordinated the overall process, organised the two workshops, coordinated the manuscript  
452 preparation, and finalised the paper for submission. YZ, RA, OHD, and HSM were external advisers who joined  
453 after the second workshop, read the manuscript draft in detail, provided in-depth critique, and approved the final  
454 paper for submission. Workgroup compositions are reported in the **appendix** (page 3f).

455

**456 Declaration of interests**

457 Actual or potential conflict of interest directly related to this work: HB: JLK (stocks). The other authors report  
458 no conflict of interest directly related to this work, but here declare interests and relationships outside the  
459 submitted work. MDu: MIAC AG (employment), Roche (consultant), Biogen (scientific advisory board), Hovid  
460 Berhad (adjudication board), Bayer Vital, Sanofi Genzyme (speaker honoraria), VasCog society (executive  
461 committee). GJB: Nestle HealthScience, Boehringer Ingelheim (consultant), European Stroke Organization,  
462 World Stroke Organization (scientific program committee). AB: Eisai, Roche (scientific advisory board),  
463 Biogen (scientific advisory board), Neurology, International Journal of Stroke (editorial board). CCh: "Moleac  
464 (consultant, research support), Cerecin, Actinogen, Eisai (scientific advisory board), World Stroke Organisation  
465 Future Leaders Programme (co-chair), Asian Society Against Dementia (chairman), Asian Oceanian  
466 Association of Neurology (secretary-treasurer). CCo: Biogen (scientific advisory board), BMS (speaker  
467 honoraria and international steering committee), Amgen (speaker honoraria), Stroke (associate editor). SD:  
468 European Stroke Organization (programme committee), World Stroke Organization (board of directors). EJ:  
469 European Stroke Organization (program committee, dementia committee, session chair, invited speaker),  
470 Abbvie Fondation Santé et Perspective (clinical research support). NSR: National Institutes of Health  
471 (U19NS115388, principal investigator), American Academy of Neurology (chair, science committee), AAN  
472 Institute Board member (ex officio); American Heart Association (ISC program committee), Stroke (associate  
473 editor), UptoDate (contributor). RAS: Recursion Pharmaceuticals, Bioxodes, PHRI McMaster University  
474 (consultant), European Stroke Organisation (workshop convenor, teaching course organiser). HB: Astrazeneca,  
475 AstraZeneca Korea Ltd, Bayer Korea, Boehringer Ingelheim Korea, Bristol Myers Squibb, Chong Gun Dang  
476 Pharmaceutical Corp., Daiichi Sankyo, Dong-A ST, GNT Pharma, Jeil Pharmaceutical Co. Ltd, Korean Drug  
477 Co. Ltd, SAMJIN Pharm., Shinpoong Pharm. Co. Ltd, Takeda Pharmaceuticals Korea Co. Lt., and Yuhan

478 Corporation (research grant), Amgen Korea, Hanmi Pharmaceutical Co. Ltd, Otsuka Korea, SK Chemicals,  
479 Viatrix Korea (speaker honoraria). HC: Biogen, Hovid Berhad (consultant), Agence Nationale de la Recherche  
480 ANR- RHU TRT\_cSVD, Association de Recherche ARNEVA, Association CADASIL-France (research  
481 support). CD: Norvartis (heart failure safety study), Eisai, Novo Nordisc (consultant). FND: Stroke Association  
482 Garfield Weston Foundation (lectureship), NRS Scotland Chief Scientist's Office (research support). ME: M. Eli  
483 Lilly and Company (research support), Prevail Therapeutics (consultant), Alzheimer's & Dementia (associate  
484 editor). AG: Canadian Institutes of Health Research, Canadian Cardiovascular Society, Alberta Innovates,  
485 Campus Alberta Neuroscience, Government of Canada – INOVAIT Program, Government of Canada – New  
486 Frontiers in Research Fund, Microvention, Alzheimer Society of Canada, Heart and Stroke Foundation of  
487 Canada, Panmure House (research support), MD Analytics, MyMedicalPanel, Figure 1, CTC Communications  
488 Corp, Atheneum, DeepBench, Research on Mind, Creative Research Designs, AlphaSights (consultant),  
489 Alexion, Biogen (honoraria), Neurology: Clinical Practice, Neurology, Stroke, Frontiers in Neurology (editorial  
490 board), SnapDx Inc., TheRounds.com, Collavidence Inc. (stock options). SG: Bayer, IQVIA/Washing  
491 University (safety monitoring committee), Lilly (consultant), UpToDate (royalties), US National Institutes of  
492 Health (research support). KGH: Minoryx Therapeutics (research support). SH: VasCog society (scientific  
493 committee). HJ: Cerebral Circulation - Cognition & Behavior (editorial board), European Stroke Organisation  
494 (guideline working groups). BYKL: VasCog society (scientific committee); Lee Hysan Postdoctoral Fellowship  
495 in Clinical Neurosciences (research support). BJM: Canadian Consortium on Neurodegeneration in Aging (co-  
496 lead of neuroimaging platform). LP: Neurology, Stroke, Cerebrovascular Diseases, European Stroke Journal,  
497 Acta Neurologica Scandinavica, Neurological Sciences (editorial board). CLS: ISTAART Vascular Cognitive  
498 Disorders PIA (program chair). JS: European Stroke Organisation (guideline committee), MRCLEAN-MED  
499 (trial executive committee). MJT: Siemens Healthineers (research support). SJV: Biogen (consultant), Therini  
500 (research support), American Heart Association (scientific program committee), International Cerebral Amyloid  
501 Angiopathy (CAA) Association (board member and scientific program committee). PV: National Institute of  
502 Health, Alzheimer's Drug Discovery Foundation (research support), Miller Medical Communications LLC  
503 (speaker honoraria). DW: Bayer, Portola, Alnylam (personal fees). MZ: European Stroke Organization (board of  
504 directors; subcommittee co-chair; WISE group co-chair), European Academy of Neurology (EANcore member;  
505 scientific panels member), Abbott, Takeda, Sanofi Genzyme (speaker honoraria); AMICUS (scientific advisory  
506 board). RAK: African Stroke Organization (chair), African Dementia Consortium (visioneer). HSM: World  
507 Stroke Organization (executive committee), Biogen (scientific advisory board). EES: Canadian Institutes of


508 Health Research, Weston Brain Institute, Weston Family Foundation (research support), McMaster University,  
509 Ottawa Heart Institute, University Health Network, Sense, and PhaseBio (research service contracts), Eli Lilly,  
510 Javelin (consultant), US National Institute of Health DISCOVERY project (data safety monitoring board),  
511 UpToDate (royalties), Stroke (associate editor). MDi: Ever Neuro Pharma, Sensome, Institut für Qualität und  
512 Wirtschaftlichkeit im Gesundheitswesen IQWiG (consultant), Bayer Vital (advisory board), Bayer Vital, Pfizer,  
513 BMS, German Society for Cardiology, University Hospital Aachen, University of Maryland (speaker  
514 honoraria). JMW: World Stroke Organization (board, policy committee), European Stroke Organisation  
515 (guideline chair), UK Dementia Research Institute Ltd (Edin002), UK Medical Research Council, Alzheimer's  
516 Research UK, and Alzheimer's Society, Fondation Leducq, MRC, BBSRC, British Heart Foundation, Stroke  
517 Association, The Galen and Hilary Weston Foundation, Dementia Platform UK (research support).

518


519 **Role of the funding source**

520 No funders had any role in the conduct or reporting of the work.

## Figures, Tables and Panels




**Figure 1: Neuroimaging features differentiating intrinsic SVD from other aetiologies and RSSIs from incidental DWI+ lesions.** A. About 15% of RSSI or incidental DWI+ lesions are due to emboli from the heart or atheroma in the large head and neck arteries. These are more likely to be larger (although there is no size cut off), tubular (along the trajectory of the perforating artery) rather than round or ovoid, associated with concurrent acute lesions in other brain regions, and in the basal ganglia rather than the centrum semiovale. The presence of one or more acute or old infarcts in the cortex in addition to a small subcortical infarct particularly increases the likelihood of embolism and these should be carefully sought. B. Lesions which cause discrete stroke symptoms (RSSI) are usually in the primary motor and sensory pathways (depicted on the left). Covert lesions are usually outside those pathways or very small (depicted on the right along with the symptoms).



**Figure 2: Range of recent (days to weeks) to long term (months to years) appearances of recent small subcortical infarcts and incidental DWI-positive lesions.** Illustrates the range of acute SVD lesion appearances (L to R), from RSSI presenting as stroke and their long-term fates (right hand columns): some lesions may disappear temporarily while passing through a period of ‘fogging’ (second from L column, white arrow head) before reaching end-stage permanent appearance after some months or longer (right-hand columns), ranging from (top row) complete cavitation (left, lacune), partial cavitation (middle), tiny lacune <3mm diameter (right); no cavitation (WMH or grey matter FLAIR hyperintensity), disappear completely (recovery), or a residual haemosiderin small (T2\* hypointense) ‘smudge’ (bottom row, L, white arrow head), or haemosiderin rim (right, arrowhead) which could be mistaken for an old haemorrhage). More detailed images are presented in the appendix.





**Figure 3: MRI features of small vessel disease.** Shows examples (upper), schematic representation (middle), and summary of MRI characteristics of SVD features. See supplemental figures for examples of the emerging feature incidental DWI+ lesion. DWI=diffusion-weighted imaging. FLAIR=fluid-attenuated inversion recovery. SWI=susceptibility-weighted imaging. T1w=T1-weighted. T2w=T2-weighted. T2\*w=T2-weighted.

## **Panel 1: Glossary of proposed terms and definitions for neuroimaging features of small vessel disease**

### **Recent small subcortical infarct:**

Neuroimaging evidence of a recent infarction in the territory of one perforating arteriole, with imaging features and clinical symptoms consistent with a lesion occurring within the previous few weeks.

### **Lacune (of presumed vascular origin)**

Round or ovoid, subcortical, fluid filled (similar signal to CSF) cavity up to 15 mm in diameter likely to be the end tissue damage from a recent small subcortical infarct, small subcortical haemorrhage, incidental DWI+ lesion, or end-stage cavitation in a WMH.

### **White matter hyperintensity (of presumed vascular origin)**

Signal abnormality of variable size in the white matter showing the following characteristics: hyperintense on T2-weighted images like FLAIR without cavitation (signal different from CSF). Lesions in the subcortical grey matter or brain stem are not included into this category unless explicitly stated – where deep grey matter and brainstem hyperintensities are included as well, the collective name should be “subcortical hyperintensities”.

### **Perivascular space**

Fluid filled space, which follows the typical course of a vessel penetrating / traversing the brain through grey or white matter; has signal intensity similar to CSF on all sequences; has a round, ovoid, or linear shape (depending on the slice direction) with a diameter commonly not exceeding 2 mm when imaged perpendicular to the course of the vessel.

### **Cerebral microbleed**

Small (usually 2 mm – 5 mm or sometimes 10 mm in size) areas of signal void with associated “blooming” on T2\* or other MRI sequences sensitive to susceptibility effects.

### **Cortical superficial siderosis**

Thin areas of hypointensity on T2\*, or other MRI sequences sensitive to susceptibility effects, in or overlying the superficial cortex, which may be confined to one gyrus and adjacent sulci, or occasionally more widespread affecting several brain regions.

### **Brain atrophy**

Brain volume loss, not related to a specific macroscopic focal injury such as trauma or infarction. Thus, the latter is not included in this measure unless explicitly stated.

### **Summary SVD score**

A grouping of accepted SVD markers that serves to summarise SVD brain burden into a single index, score, or unitary construct.

### **(Old) cortical cerebral microinfarct**

Small lesions appearing hypointense on T1-weighted, hyperintense on T2-weighted/FLAIR, and isointense on T2\*-weighted MRI, operationally defined to be strictly cortical and with an upper size limit of 4 mm.

## References

1. Wardlaw JM, Smith C, Dichgans M. Small vessel disease: mechanisms and clinical implications. *Lancet Neurol* 2019; **18**(7): 684-96.
2. Wardlaw JM, Smith EE, Biessels GJ, et al. Neuroimaging standards for research into small vessel disease and its contribution to ageing and neurodegeneration. *Lancet Neurol* 2013; **12**(8): 822-38.
3. Wardlaw JM, DeBette S, Jokinen H, et al. ESO Guideline on covert cerebral small vessel disease. *Eur Stroke J* 2021; **6**(2): IV.
4. Cho AH, Kwon HS, Lee MH, et al. Hemorrhagic Focus Within the Recent Small Subcortical Infarcts on Long-Term Follow-Up Magnetic Resonance Imaging. *Stroke* 2022; **53**(4): e139-e40.
5. Pinter D, Gatttringer T, Enzinger C, et al. Longitudinal MRI dynamics of recent small subcortical infarcts and possible predictors. *J Cereb Blood Flow Metab* 2019; **39**(9): 1669-77.
6. Duering M, Adam R, Wollenweber FA, et al. Within-lesion heterogeneity of subcortical DWI lesion evolution, and stroke outcome: A voxel-based analysis. *J Cereb Blood Flow Metab* 2020; **40**(7): 1482-91.
7. Loos CMJ, Makin SDJ, Staals J, Dennis MS, van Oostenbrugge RJ, Wardlaw JM. Long-Term Morphological Changes of Symptomatic Lacunar Infarcts and Surrounding White Matter on Structural Magnetic Resonance Imaging. *Stroke* 2018; **49**(5): 1183-8.
8. Gatttringer T, Valdes Hernandez M, Heye A, et al. Predictors of Lesion Cavitation After Recent Small Subcortical Stroke. *Transl Stroke Res* 2020; **11**(3): 402-11.
9. Gesierich B, Duchesnay E, Jouvent E, et al. Features and Determinants of Lacune Shape: Relationship With Fiber Tracts and Perforating Arteries. *Stroke* 2016; **47**(5): 1258-64.
10. Ter Telgte A, Wiegertjes K, Gesierich B, et al. Contribution of acute infarcts to cerebral small vessel disease progression. *Ann Neurol* 2019; **86**(4): 582-92.
11. Zhang J, Han F, Liang X, et al. Lacune and Large Perivascular Space: Two Kinds of Cavities Are of Different Risk Factors and Stroke Risk. *Cerebrovasc Dis* 2020; **49**(5): 522-30.
12. Duering M, Csanadi E, Gesierich B, et al. Incident lacunes preferentially localize to the edge of white matter hyperintensities: insights into the pathophysiology of cerebral small vessel disease. *Brain* 2013; **136**(Pt 9): 2717-26.

13. DeBette S, Schilling S, Duperron MG, Larsson SC, Markus HS. Clinical Significance of Magnetic Resonance Imaging Markers of Vascular Brain Injury: A Systematic Review and Meta-analysis. *JAMA Neurol* 2019; **76**(1): 81-94.
14. I. S. T. collaborative group. Association between brain imaging signs, early and late outcomes, and response to intravenous alteplase after acute ischaemic stroke in the third International Stroke Trial (IST-3): secondary analysis of a randomised controlled trial. *Lancet Neurol* 2015; **14**(5): 485-96.
15. Appleton JP, Woodhouse LJ, Adami A, et al. Imaging markers of small vessel disease and brain frailty, and outcomes in acute stroke. *Neurology* 2020; **94**(5): e439-e52.
16. Ling Y, Chabriat H. Incident cerebral lacunes: A review. *J Cereb Blood Flow Metab* 2020; **40**(5): 909-21.
17. Georgakis MK, Duering M, Wardlaw JM, Dichgans M. WMH and long-term outcomes in ischemic stroke: A systematic review and meta-analysis. *Neurology* 2019; **92**(12): e1298-e308.
18. Clancy U, Gilmartin D, Jochems ACC, Knox L, Doubal FN, Wardlaw JM. Neuropsychiatric symptoms associated with cerebral small vessel disease: a systematic review and meta-analysis. *Lancet Psychiatry* 2021; **8**(3): 225-36.
19. Hamilton OKL, Cox SR, Okely JA, et al. Cerebral small vessel disease burden and longitudinal cognitive decline from age 73 to 82: the Lothian Birth Cohort 1936. *Transl Psychiatry* 2021; **11**(1): 376.
20. Hamilton OKL, Backhouse EV, Janssen E, et al. Cognitive impairment in sporadic cerebral small vessel disease: A systematic review and meta-analysis. *Alzheimers Dement* 2021; **17**(4): 665-85.
21. Jochems ACC, Arteaga C, Chappell F, et al. Longitudinal Changes of White Matter Hyperintensities in Sporadic Small Vessel Disease: A Systematic Review and Meta-analysis. *Neurology* 2022.
22. Maillard P, Fletcher E, Harvey D, et al. White matter hyperintensity penumbra. *Stroke* 2011; **42**(7): 1917-22.
23. Wardlaw JM, Chappell FM, Valdes Hernandez MDC, et al. White matter hyperintensity reduction and outcomes after minor stroke. *Neurology* 2017; **89**(10): 1003-10.
24. Blair GW, Thrippleton MJ, Shi Y, et al. Intracranial hemodynamic relationships in patients with cerebral small vessel disease. *Neurology* 2020; **94**(21): e2258-e69.
25. Palta P, Sharrett AR, Wei J, et al. Central Arterial Stiffness Is Associated With Structural Brain Damage and Poorer Cognitive Performance: The ARIC Study. *J Am Heart Assoc* 2019; **8**(2): e011045.

26. Keith J, Gao FQ, Noor R, et al. Collagenosis of the Deep Medullary Veins: An Underrecognized Pathologic Correlate of White Matter Hyperintensities and Periventricular Infarction? *J Neuropathol Exp Neurol* 2017; **76**(4): 299-312.
27. Stewart CR, Stringer MS, Shi Y, Thrippleton MJ, Wardlaw JM. Associations Between White Matter Hyperintensity Burden, Cerebral Blood Flow and Transit Time in Small Vessel Disease: An Updated Meta-Analysis. *Front Neurol* 2021; **12**: 647848.
28. Caligiuri ME, Perrotta P, Augimeri A, Rocca F, Quattrone A, Cherubini A. Automatic Detection of White Matter Hyperintensities in Healthy Aging and Pathology Using Magnetic Resonance Imaging: A Review. *Neuroinformatics* 2015; **13**(3): 261-76.
29. Balakrishnan R, Valdes Hernandez MDC, Farrall AJ. Automatic segmentation of white matter hyperintensities from brain magnetic resonance images in the era of deep learning and big data - A systematic review. *Comput Med Imaging Graph* 2021; **88**: 101867.
30. Smith EE, Biessels GJ, De Guio F, et al. Harmonizing brain magnetic resonance imaging methods for vascular contributions to neurodegeneration. *Alzheimers Dement (Amst)* 2019; **11**: 191-204.
31. Wardlaw JM, Benveniste H, Nedergaard M, et al. Perivascular spaces in the brain: anatomy, physiology and pathology. *Nat Rev Neurol* 2020; **16**(3): 137-53.
32. Hernandez Mdel C, Piper RJ, Wang X, Deary IJ, Wardlaw JM. Towards the automatic computational assessment of enlarged perivascular spaces on brain magnetic resonance images: a systematic review. *J Magn Reson Imaging* 2013; **38**(4): 774-85.
33. Jochems ACC, Blair GW, Stringer MS, et al. Relationship Between Venules and Perivascular Spaces in Sporadic Small Vessel Diseases. *Stroke* 2020; **51**(5): 1503-6.
34. Bouvy WH, Geurts LJ, Kuijf HJ, et al. Assessment of blood flow velocity and pulsatility in cerebral perforating arteries with 7-T quantitative flow MRI. *NMR Biomed* 2016; **29**(9): 1295-304.
35. Francis F, Ballerini L, Wardlaw JM. Perivascular spaces and their associations with risk factors, clinical disorders and neuroimaging features: A systematic review and meta-analysis. *Int J Stroke* 2019; **14**(4): 359-71.
36. Duperron MG, Tzourio C, Sargurupremraj M, et al. Burden of Dilated Perivascular Spaces, an Emerging Marker of Cerebral Small Vessel Disease, Is Highly Heritable. *Stroke* 2018; **49**(2): 282-7.

37. Charidimou A, Boulouis G, Frosch MP, et al. The Boston criteria version 2.0 for cerebral amyloid angiopathy: a multicentre, retrospective, MRI-neuropathology diagnostic accuracy study. *Lancet Neurol* 2022; **21**(8): 714-25.
38. Piantino J, Boespflug EL, Schwartz DL, et al. Characterization of MR Imaging-Visible Perivascular Spaces in the White Matter of Healthy Adolescents at 3T. *AJNR Am J Neuroradiol* 2020; **41**(11): 2139-45.
39. Barnes A, Ballerini L, Valdes Hernandez MDC, et al. Topological relationships between perivascular spaces and progression of white matter hyperintensities: A pilot study in a sample of the Lothian Birth Cohort 1936. *Front Neurol* 2022; **13**: 889884.
40. Del Brutto OH, Mera RM, Del Brutto VJ, Castillo PR. Enlarged basal ganglia perivascular spaces and sleep parameters. A population-based study. *Clin Neurol Neurosurg* 2019; **182**: 53-7.
41. Potter GM, Chappell FM, Morris Z, Wardlaw JM. Cerebral perivascular spaces visible on magnetic resonance imaging: development of a qualitative rating scale and its observer reliability. *Cerebrovasc Dis* 2015; **39**(3-4): 224-31.
42. Ballerini L, Booth T, Valdes Hernandez MDC, et al. Computational quantification of brain perivascular space morphologies: Associations with vascular risk factors and white matter hyperintensities. A study in the Lothian Birth Cohort 1936. *Neuroimage Clin* 2020; **25**: 102120.
43. Duperron M-G, Knol MJ, Grand QL, et al. Genomics of perivascular space burden unravels early mechanisms of cerebral small vessel disease. *Alzheimer's & Dementia* 2022; **18**(S11): e064953.
44. van Veluw SJ, Scherlek AA, Freeze WM, et al. Different microvascular alterations underlie microbleeds and microinfarcts. *Ann Neurol* 2019; **86**(2): 279-92.
45. Jolink WMT, van Veluw SJ, Zwanenburg JJM, et al. Histopathology of Cerebral Microinfarcts and Microbleeds in Spontaneous Intracerebral Hemorrhage. *Transl Stroke Res* 2022.
46. van Veluw SJ, Biessels GJ, Klijn CJ, Rozemuller AJ. Heterogeneous histopathology of cortical microbleeds in cerebral amyloid angiopathy. *Neurology* 2016; **86**(9): 867-71.
47. Pasi M, Charidimou A, Boulouis G, et al. Mixed-location cerebral hemorrhage/microbleeds: Underlying microangiopathy and recurrence risk. *Neurology* 2018; **90**(2): e119-e26.
48. Best JG, Ambler G, Wilson D, et al. Development of imaging-based risk scores for prediction of intracranial haemorrhage and ischaemic stroke in patients taking antithrombotic therapy after ischaemic stroke or transient ischaemic attack: a pooled analysis of individual patient data from cohort studies. *Lancet Neurol* 2021; **20**(4): 294-303.

49. O'Donnell MJ, Eikelboom JW, Yusuf S, et al. Effect of apixaban on brain infarction and microbleeds: AVERROES-MRI assessment study. *Am Heart J* 2016; **178**: 145-50.
50. Al-Shahi Salman R, Minks DP, Mitra D, et al. Effects of antiplatelet therapy on stroke risk by brain imaging features of intracerebral haemorrhage and cerebral small vessel diseases: subgroup analyses of the RESTART randomised, open-label trial. *Lancet Neurol* 2019; **18**(7): 643-52.
51. Shoamanesh A, Pearce LA, Bazan C, et al. Microbleeds in the Secondary Prevention of Small Subcortical Strokes Trial: Stroke, mortality, and treatment interactions. *Ann Neurol* 2017; **82**(2): 196-207.
52. Charidimou A, Boulouis G, Greenberg SM, Viswanathan A. Cortical superficial siderosis and bleeding risk in cerebral amyloid angiopathy: A meta-analysis. *Neurology* 2019; **93**(24): e2192-e202.
53. Del Brutto OH, Lama J, Zambrano M, Del Brutto VJ. Neurocysticercosis is a neglected microbleed mimic. a cautionary note for stroke neurologists. *Eur Neurol* 2014; **72**(5-6): 306-8.
54. Chesebro AG, Amarante E, Lao PJ, Meier IB, Mayeux R, Brickman AM. Automated detection of cerebral microbleeds on T2\*-weighted MRI. *Sci Rep* 2021; **11**(1): 4004.
55. Charidimou A, Perosa V, Frosch MP, Scherlek AA, Greenberg SM, van Veluw SJ. Neuropathological correlates of cortical superficial siderosis in cerebral amyloid angiopathy. *Brain* 2020; **143**(11): 3343-51.
56. Koemans EA, Voigt S, Rasing I, et al. Cerebellar Superficial Siderosis in Cerebral Amyloid Angiopathy. *Stroke* 2022; **53**(2): 552-7.
57. Smith EE, Charidimou A, Ayata C, Werring DJ, Greenberg SM. Cerebral Amyloid Angiopathy-Related Transient Focal Neurologic Episodes. *Neurology* 2021; **97**(5): 231-8.
58. Charidimou A, Schmitt A, Wilson D, et al. The Cerebral Haemorrhage Anatomical RaTing inStrument (CHARTS): Development and assessment of reliability. *J Neurol Sci* 2017; **372**: 178-83.
59. Rodrigues MA, Samarasekera N, Lerpiniere C, et al. The Edinburgh CT and genetic diagnostic criteria for lobar intracerebral haemorrhage associated with cerebral amyloid angiopathy: model development and diagnostic test accuracy study. *Lancet Neurol* 2018; **17**(3): 232-40.
60. Jouvent E, Duering M, Chabriat H. Cerebral Autosomal Dominant Arteriopathy With Subcortical Infarcts and Leukoencephalopathy: Lessons From Neuroimaging. *Stroke* 2020; **51**(1): 21-8.
61. Duering M, Righart R, Wollenweber FA, Zietemann V, Gesierich B, Dichgans M. Acute infarcts cause focal thinning in remote cortex via degeneration of connecting fiber tracts. *Neurology* 2015; **84**(16): 1685-92.

62. van Veluw SJ, Shih AY, Smith EE, et al. Detection, risk factors, and functional consequences of cerebral microinfarcts. *Lancet Neurol* 2017; **16**(9): 730-40.
63. De Guio F, Duering M, Fazekas F, et al. Brain atrophy in cerebral small vessel diseases: Extent, consequences, technical limitations and perspectives: The HARNESS initiative. *J Cereb Blood Flow Metab* 2020; **40**(2): 231-45.
64. Subotic A, McCreary CR, Saad F, et al. Cortical Thickness and Its Association with Clinical Cognitive and Neuroimaging Markers in Cerebral Amyloid Angiopathy. *J Alzheimers Dis* 2021; **81**(4): 1663-71.
65. De Guio F, Germanaud D, Lefevre J, et al. Alteration of the Cortex Shape as a Proxy of White Matter Swelling in Severe Cerebral Small Vessel Disease. *Front Neurol* 2019; **10**: 753.
66. De Guio F, Reyes S, Duering M, Pirpamer L, Chabriat H, Jouvent E. Decreased T1 contrast between gray matter and normal-appearing white matter in CADASIL. *AJNR Am J Neuroradiol* 2014; **35**(1): 72-6.
67. Paradise MB, Shepherd CE, Wen W, Sachdev PS. Neuroimaging and neuropathology indices of cerebrovascular disease burden: A systematic review. *Neurology* 2018; **91**(7): 310-20.
68. Staals J, Makin SD, Doubal FN, Dennis MS, Wardlaw JM. Stroke subtype, vascular risk factors, and total MRI brain small-vessel disease burden. *Neurology* 2014; **83**(14): 1228-34.
69. Lau KK, Li L, Schulz U, et al. Total small vessel disease score and risk of recurrent stroke: Validation in 2 large cohorts. *Neurology* 2017; **88**(24): 2260-7.
70. Staals J, Booth T, Morris Z, et al. Total MRI load of cerebral small vessel disease and cognitive ability in older people. *Neurobiol Aging* 2015; **36**(10): 2806-11.
71. Charidimou A, Martinez-Ramirez S, Reijmer YD, et al. Total Magnetic Resonance Imaging Burden of Small Vessel Disease in Cerebral Amyloid Angiopathy: An Imaging-Pathologic Study of Concept Validation. *JAMA Neurol* 2016; **73**(8): 994-1001.
72. Dickie DA, Valdes Hernandez MDC, Makin SD, et al. The brain health index: Towards a combined measure of neurovascular and neurodegenerative structural brain injury. *Int J Stroke* 2018; **13**(8): 849-56.
73. Ter Telgte A, Scherlek AA, Reijmer YD, et al. Histopathology of diffusion-weighted imaging-positive lesions in cerebral amyloid angiopathy. *Acta Neuropathol* 2020; **139**(5): 799-812.
74. Raja R, Rosenberg G, Caprihan A. Review of diffusion MRI studies in chronic white matter diseases. *Neurosci Lett* 2019; **694**: 198-207.



75. Maillard P, Lu H, Arfanakis K, et al. Instrumental validation of free water, peak-width of skeletonized mean diffusivity, and white matter hyperintensities: MarkVCID neuroimaging kits. *Alzheimers Dement (Amst)* 2022; **14**(1): e12261.
76. Maillard P, Fletcher E, Singh B, et al. Cerebral white matter free water: A sensitive biomarker of cognition and function. *Neurology* 2019; **92**(19): e2221-e31.
77. Duering M, Finsterwalder S, Baykara E, et al. Free water determines diffusion alterations and clinical status in cerebral small vessel disease. *Alzheimers Dement* 2018; **14**(6): 764-74.
78. Dewenter A, Gesierich B, Ter Telgte A, et al. Systematic validation of structural brain networks in cerebral small vessel disease. *J Cereb Blood Flow Metab* 2022; **42**(6): 1020-32.
79. Finsterwalder S, Vlegels N, Gesierich B, et al. Small vessel disease more than Alzheimer's disease determines diffusion MRI alterations in memory clinic patients. *Alzheimers Dement* 2020; **16**(11): 1504-14.
80. Dewenter A, Jacob MA, Cai M, et al. Disentangling the effects of Alzheimer's and small vessel disease on white matter fibre tracts. *Brain* 2022.
81. Valdes Hernandez Mdel C, Maconick LC, Tan EM, Wardlaw JM. Identification of mineral deposits in the brain on radiological images: a systematic review. *Eur Radiol* 2012; **22**(11): 2371-81.
82. Kalaria RN, Sepulveda-Falla D. Cerebral Small Vessel Disease in Sporadic and Familial Alzheimer Disease. *Am J Pathol* 2021; **191**(11): 1888-905.
83. Ayton S, Fazlollahi A, Bourgeat P, et al. Cerebral quantitative susceptibility mapping predicts amyloid-beta-related cognitive decline. *Brain* 2017; **140**(8): 2112-9.
84. Quarles CC, Bell LC, Stokes AM. Imaging vascular and hemodynamic features of the brain using dynamic susceptibility contrast and dynamic contrast enhanced MRI. *Neuroimage* 2019; **187**: 32-55.
85. Alsop DC, Detre JA, Golay X, et al. Recommended implementation of arterial spin-labeled perfusion MRI for clinical applications: A consensus of the ISMRM perfusion study group and the European consortium for ASL in dementia. *Magn Reson Med* 2015; **73**(1): 102-16.
86. Sleight E, Stringer MS, Marshall I, Wardlaw JM, Thrippleton MJ. Cerebrovascular Reactivity Measurement Using Magnetic Resonance Imaging: A Systematic Review. *Front Physiol* 2021; **12**: 643468.
87. Vikner T, Karalija N, Eklund A, et al. 5-Year Associations among Cerebral Arterial Pulsatility, Perivascular Space Dilation, and White Matter Lesions. *Ann Neurol* 2022; **92**(5): 871-81.

88. Thrippleton MJ, Backes WH, Sourbron S, et al. Quantifying blood-brain barrier leakage in small vessel disease: Review and consensus recommendations. *Alzheimers Dement* 2019; **15**(6): 840-58.
89. Smith EE, Duchesne S, Gao F, et al. Vascular Contributions to Neurodegeneration: Protocol of the COMPASS-ND Study. *Can J Neurol Sci* 2021; **48**(6): 799-806.
90. Lu H, Kashani AH, Arfanakis K, et al. MarkVCID cerebral small vessel consortium: II. Neuroimaging protocols. *Alzheimers Dement* 2021; **17**(4): 716-25.
91. Bouvy WH, Biessels GJ, Kuijf HJ, Kappelle LJ, Luijten PR, Zwanenburg JJ. Visualization of perivascular spaces and perforating arteries with 7 T magnetic resonance imaging. *Invest Radiol* 2014; **49**(5): 307-13.
92. van den Brink H, Doubal FN, Duering M. Advanced MRI in cerebral small vessel disease. *Int J Stroke* 2022: 17474930221091879.
93. Kuijf HJ, Biesbroek JM, De Bresser J, et al. Standardized Assessment of Automatic Segmentation of White Matter Hyperintensities and Results of the WMH Segmentation Challenge. *IEEE Trans Med Imaging* 2019; **38**(11): 2556-68.
94. Jokinen H, Koikkalainen J, Laakso HM, et al. Global Burden of Small Vessel Disease-Related Brain Changes on MRI Predicts Cognitive and Functional Decline. *Stroke* 2020; **51**(1): 170-8.
95. Schirmer MD, Dalca AV, Sridharan R, et al. White matter hyperintensity quantification in large-scale clinical acute ischemic stroke cohorts - The MRI-GENIE study. *Neuroimage Clin* 2019; **23**: 101884.
96. Markus HS, van Der Flier WM, Smith EE, et al. Framework for Clinical Trials in Cerebral Small Vessel Disease (FINESSE): A Review. *JAMA Neurol* 2022.
97. White WB, Wakefield DB, Moscufo N, et al. Effects of Intensive Versus Standard Ambulatory Blood Pressure Control on Cerebrovascular Outcomes in Older People (INFINITY). *Circulation* 2019; **140**(20): 1626-35.
98. SPRINT MIND Investigators for the SPRINT Research Group, Williamson JD, Pajewski NM, et al. Effect of Intensive vs Standard Blood Pressure Control on Probable Dementia: A Randomized Clinical Trial. *JAMA* 2019; **321**(6): 553-61.
99. Akinyemi RO, Ovbiagele B, Adeniji OA, et al. Stroke in Africa: profile, progress, prospects and priorities. *Nat Rev Neurol* 2021; **17**(10): 634-56.
100. McGuire AL, Gabriel S, Tishkoff SA, et al. The road ahead in genetics and genomics. *Nat Rev Genet* 2020; **21**(10): 581-96.

**Table 1: Proposed image acquisition standards for neuroimaging features of SVD.**

	Purpose*	Orientation	Target slice thickness, in-plane resolution	Comment
<b>Minimum essential sequences (e.g., for clinical or large-scale epidemiological studies, generally available on most MR scanners)</b>				
T1-weighted	To discriminate lacunes from PVS; for discriminating grey from white matter, for detecting CMI, and for measuring brain tissue volumes	3D	1-mm isotropic voxels	Allows post-acquisition reformatting for visualising full extent and orientation of many features
Diffusion imaging (typically with $\leq 6$ encoded directions and one $b$ -value shell)	To detect acute ischaemic lesions; positive for up to several weeks after cerebrovascular event	2D axial	3-5 mm, 1-2 mm x 1-2 mm	Reduced signal on apparent diffusion coefficient map helps identifying acute from subacute or old lesions. Optional acquisition of additional diffusion-encoding directions allows more detailed characterisation but with increased acquisition time (see research sequences)
T2-weighted	To characterise brain structure; to differentiate lacunes from WMH and PVS; to identify old infarcts	2D axial or 3D	2D: 1-2 mm, 1 mm x 1 mm 3D: 1-mm isotropic voxels	Allows post-acquisition reformatting for visualising full extent and orientation of many lesions
FLAIR	To identify WMH, established cortical or large subcortical infarcts, and CMI; to differentiate WMH from PVS and lacunes	2D axial or 3D	2D: 1-2 mm, 1 mm x 1 mm 3D: 1-mm isotropic voxels	Allows post-acquisition reformatting for visualising full extent and orientation of many lesions
Susceptibility imaging (select at least one)				
a) T2*-weighted GRE	To detect intracerebral haemorrhage, CMB, and cSS	2D axial	3-5 mm, 1 mm x 1 mm	Reliable routine sequence for detection of haemorrhagic markers
b) SWI or equivalent	To detect intracerebral haemorrhage, CMB, and cSS. Potentially more sensitive to haemosiderin. To measure intracranial volume (3D approaches)	2D axial or 3D	2D: 3-5 mm, 1 mm x 1 mm 3D: 1-mm isotropic voxels	Enhanced detection of CMB compared to T2*-weighted GRE imaging but more sensitive to artifacts including motion
MR angiography (MRA)	To detect stenosis in larger vessel in neck and brain (i.e., vertebral, basilar, internal carotid, middle cerebral, anterior cerebral, or posterior cerebral arteries)	3D post contrast or 3D TOF (intracranial)	1-mm isotropic voxels	Axial, coronal, sagittal reformats and projections examined, Only large vessels visible at 1.5 T or 3 T (see <i>mMRA</i> below for imaging smaller arteries)
<b>Research sequences (i.e., require research expertise)</b>				
Advanced diffusion imaging (typically with many directions, higher $b$ -values, and multiple shells)	To enable sophisticated (biophysical) modelling of microscopic tissue changes	2D axial	$\leq 2$ -mm isotropic voxels	Allows for more advanced modelling of water diffusion in white matter that may provide superior quantitative measurements
Advanced susceptibility imaging (R2* mapping or QSM)	To provide quantitative measures of susceptibility changes in tissue	2D axial or 3D	2D: 3-5 mm, 2 mm x 2 mm 3D: 1-mm isotropic voxels	Uses an SWI-like GRE or emerging 3D EPI acquisition, but needs post-processing to produce estimates of changes to R2* or estimates of susceptibility

Perfusion imaging				
a) ASL	To measure blood perfusion in brain tissue; quantitative, with assumptions	2D axial or 3D (preferred)	2D: 3-5 mm, 2 mm x 2 mm 3D: $\leq 8$ mm x 4 mm x 4 mm voxels	Acquisition and processing fairly standardised; Useful for GM perfusion visual or quantitative assessment; contrast injection <u>not</u> needed
b) DCE or DSC	To semi-quantitatively measure blood perfusion in brain tissue	2D axial	3-5 mm, 2 mm x 2 mm	Needs intravenous contrast injection and complex post-processing; optimum acquisition and processing not yet confirmed for T1- (DCE) or T2*-weighted (DSC) approaches
Permeability imaging	To estimate permeability-surface area product of the blood-brain barrier	2D axial or 3D; sequential pre- and post-contrast	3-5 mm, 2 mm x 2 mm 2-5mm, 1-2 x 1-2 mm	Needs intravenous contrast injection; complex post-processing; methods are improving
Brain activation imaging using task-based fMRI or resting-state fMRI	To measure brain function or vascular reactivity	2D axial	3-5 mm, 2 mm x 2 mm or approx. 3-mm isotropic voxels	Complex set up, acquisition and processing, plus need to provide appropriate stimuli in task-based fMRI
Magnetization transfer (MT) imaging	To detect demyelination and axonal loss	2D axial or 3D	2D: 3-5 mm, 1 mm x 1 mm 3D: 1-mm isotropic voxels	Requires experience in acquisition and interpretation; two measurements (with and without MT-pulse); MT ratio is confounded by T1 and B1 <sup>+</sup>
R1 Mapping	To estimate water content of tissue	2D axial or 3D	2D: 3-5 mm, 2 mm x 2 mm 3D: 1-mm isotropic voxels	Requires experience in acquisition and interpretation; also sensitive to myelin, paramagnetics, so not specific to water
Flow-based Imaging (e.g., PC)	To measure blood flow dynamics and pulsatility, typically in larger vessels in the neck and brain.	uncertain, emerging method	uncertain, emerging method	Promising experimental approach
mMRA (micro-atheroma/arteriolar Imaging)	To visualise perforating artery wall and lumen anatomy, and atheroma	uncertain, emerging method	uncertain, emerging method	Promising experimental approach that requires >3 T scanner
Double inversion recovery (DIR)	To enhance detection of CMI	uncertain, emerging method	uncertain, emerging method	Promising experimental approach that requires $\geq 3$ T scanner

ASL=arterial spin labelling. CMB-cerebral microbleed. CMI-cortical microinfarct. cSS=cortical superficial siderosis. DCE=dynamic contrast-enhancement. DIR=double inversion recovery. DSC=dynamic susceptibility contrast. FLAIR=fluid-attenuated inversion recovery. fMRI=functional MRI. GRE=gradient-recalled echo. MRA=magnetic resonance angiography. MP-RAGE=magnetisation-prepared rapid acquisition with gradient echo. MT=magnetisation transfer. PC=phase contrast. PVS=perivascular space. QSM=quantitative susceptibility mapping. R1=1/T1. R2\*=1/T2\*. SWI=susceptibility-weighted imaging. TOF=Time of flight. WMH=white matter hyperintensity

\*MRI at 3.0 T is preferred, minimum recommended field strength is 1.5 T. However, these standards are listed as minimum and essential to research-only applications. These categories are not absolute; purposes are variable, and will vary with investigators' interest, expertise, and available technology.

**Table 2: Image Analysis approaches for small vessel disease**

Endpoint	Measure of interest	Analysis standard	Suggested quality metrics	Automation status	Validation status	General comments
<b>Point lesions (apparent size of a few voxels)</b>	(old) cortical cerebral microinfarct	Visual count	Recall, false positive count, F1  Kappa and ICC are used but can be sensitive to outliers.	None, besides one semi-automatic single-cohort AI approach	None.	Depending on the apparent size of a lesion, it can be more appropriate to consider it as a point lesion or a volumetric lesion (or both). Quality metrics should be chosen accordingly.
	Cerebral microbleed	Validated visual rating scales (e.g., MARS, BOMBS)		Various semi-automatic and fully automatic approaches. False positive censoring needed.	Some studies on repeatability and reproducibility, mostly in single centres. Technical validation in biomedical challenges is pending.	
	Perivascular space	Visual rating, some validated rating scales		Some automatic approaches.	Technical validation in biomedical challenges is pending.	
<b>Volumetric lesions (apparent size of many voxels)</b>	Lacune	Visual count	Dice Similarity Coefficient, (modified) Hausdorff distance (or other surface distances), volumetric similarity.	A few automatic approaches.	Technical validation in biomedical challenges is pending.	
	Recent small subcortical infarct	Visual inspection/count, manual delineations		Very few automatic approaches.	None.	
	White matter hyperintensity	Validated visual rating scales (Fazekas, ARWMC), manual delineations		Many semi and fully automated approaches	Repeatability and reproducibility established in multiple centres and biomedical challenges.	

<b>Non-lesion outcomes</b>	Brain atrophy	Validated visual rating scales (e.g., GCA).	Intra/inter observer variation. For automatic methods: see volumetric lesions.	Many fully automated approaches. Some require manual corrections.	Repeatability and reproducibility established in multiple centres and biomedical challenges.	
	Perfusion	Visual inspection	Unknown	Unknown	Unknown	Various parameters can be derived with dedicated software packages, but objective quality metrics and technical validation is currently lacking or rare.
	Connectivity	Visual inspection	Unknown	Some software packages exist for individual steps of the analysis workflow.	Unknown	
	Microstructural integrity and diffusion imaging-based metrics	Unknown	ICC or Bland-Altman to evaluate repeatability.	Many semi-automated and some fully automated approaches.	Some studies on a subset of possible measures-of-interest show good (NODDI) to excellent (DTI, DKI) repeatability and reproducibility	Harmonisation of acquisition parameters is advised in prospective multi-centre studies.
	Lesion-symptom mapping; directly inferring clinical outcomes from (pre-processed) images.	Comparison to clinical outcomes	Cross-validation machine learning	Some software packages for (voxel-based) lesion-symptom mapping		

AI=artificial intelligence. ARWMC=age-related white matter changes. DKI=diffusion kurtosis imaging. DTI=diffusion tensor imaging. GCA= Global cortical atrophy. ICC=intra-class correlation coefficient. NODDI=neurite orientation dispersion and density imaging.

## STRIVE-2 Appendix

### Table of Contents

<b>Supplemental methods .....</b>	<b>2</b>
Approach.....	2
Composition of working groups .....	3
Literature search strategy.....	5
Recent small subcortical infarct and lacune of presumed vascular origin.....	5
White matter hyperintensity of presumed vascular origin.....	5
Cerebral microbleed.....	6
Perivascular space.....	6
Brain atrophy .....	6
Summary SVD score.....	7
Microinfarct .....	7
<b>Supplemental text, tables and references.....</b>	<b>8</b>
Recent small subcortical infarcts on CT imaging.....	8
Incidental DWI-positive lesions .....	8
Non-intrinsic vascular causes of recent small subcortical infarcts .....	8
Perforating Arteries.....	9
Venules .....	9
Intracranial atherosclerosis .....	9
Quantitative susceptibility mapping for measuring iron deposition.....	9
Supplemental table 1. Advances in understanding of specific features and implications of traditional SVD features and in their detection and characterisation.....	10
Supplemental table 2: MRI markers of cerebrovascular function.....	13
Supplemental references .....	15
<b>Supplemental panels .....</b>	<b>23</b>
Supplemental panel 1: List of non-recommended terms .....	23
Supplemental panel 2: Terms for structural quantitative imaging markers of SVD brain damage.....	24
Supplemental panel 3: Proposed reporting standards for neuroimaging studies of small vessel disease.....	25
Supplemental panel 4: Questions to be addressed in future imaging studies of small vessel disease.....	27
<b>Supplemental figures .....</b>	<b>29</b>

## Supplemental methods

### Approach

We established a diverse group of 50 experts consisting of original contributors to STRIVE-1 and new contributors, from Europe, Asia, Australia, and North America, with expertise including neurology, neuroradiology, neuropathology, epidemiology, neuropsychology, medical physics, image analysis, stroke, gerontology, and dementia. We considered a high level of current research activity in SVD to be an essential criterion for participation in STRIVE-2. We allocated the 50 experts to 10 topic-focussed working groups each with a lead (**see below**). Each group included emerging and senior researchers, a mix of expertise and geographical location.

In May 2021, we convened in a one-day virtual meeting to discuss advances since 2013 in understanding of core SVD features described in STRIVE-1, including imaging features that were emerging at the time of publication that are now established, novel imaging features which have emerged since publication, structural and functional metrics, and image acquisition and analysis methods. We focused primarily on MRI methods but also considered CT. We did not include Positron Emission Tomography (PET) or other non-MRI/non-CT based methods due to space and a relative lack of data on SVD in the case of PET imaging. Prior to the meeting, each group prepared a short presentation of the main advances in their topic, which were each then discussed in detail by the group.

Following the meeting, each topic workgroup prepared text summarising the new knowledge since 2013. We performed systematic searches to identify relevant literature and to assess for harmonisation of terminologies since 2013 (**see below**). Using a questionnaire that adhered to the format of the STRIVE-1 acquisition recommendations,<sup>3</sup> we surveyed the STRIVE group on their current clinical and research acquisition protocols. Survey response rate was 41/50 (82%) with 22 respondents being primarily clinicians and 29 being primarily research; 11 were clinician-researchers.

We held a second meeting in October 2022 to present and discuss the findings, particularly to carefully consider if we should propose revised terminology for any features. Like STRIVE-1, new external advisors originating from Africa, South America, China, and Europe joined the group for additional review and comment.

Methods were based on the Delphi principle, where workgroups discussed and prepared a text proposal, followed by two workshops, and an anonymous online survey on open topics, before editing and finalising the consensus document.<sup>3</sup>

An important purpose of STRIVE-1 was to harmonise SVD terminology to improve scientific communication and thus accelerate understanding of SVD pathophysiology, epidemiology, and treatment. STRIVE-2 workgroups, therefore, considered if the STRIVE-1 terminology required revision and where new scientific knowledge was available. We provided a template to assist in preparation of text and, as in STRIVE-1, to focus on achieving a consensus on terminology, definitions, image acquisition, analysis and reporting standards, following principles endorsed by the Enhancing the QUALity and Transparency Of health Research (EQUATOR) Guideline Network, and to update the current STRIVE-1 entry on EQUATOR (Reporting guidelines | The EQUATOR Network, [equator-network.org](http://equator-network.org)).

As in STRIVE-1, we agreed the important principle that terms and definitions should *reflect the imaging characteristics and avoid presumptions about mechanisms or pathological changes, especially when these are incompletely understood, so as not to prejudice future studies of SVD* – i.e., to *‘describe what you see and not what you think you see’*. Finally, since judgement is required in the use of any classification system and understanding of the terminology and consistent use is needed to improve clinical practice, we provide further details in this **appendix** including features with unusual appearances, caveats in interpretation, temporal evolution of, and boundaries between features.



## **Composition of working groups**

### Adoption of STRIVE-1 terminology

Brown, Rosalind  
Helmer, Karl  
Jokinen, Hanna  
Smith, Eric  
ter Telgte, Annemieke (lead)

### Update on imaging features defined in STRIVE-1, part 1 (RSSI, lacune, WMH, PVS)

Chabriat, Hugues  
Debette, Stéphanie (lead)  
Maillard, Pauline  
Pantoni, Leonardo  
Rudilosso, Salvatore  
Smith, Colin  
Wardlaw, Joanna

### Update on imaging features defined in STRIVE-1, part 2 (CMB, cSS, ICH)

Al-Shahi Salman, Rustam  
Cordonnier, Charlotte (lead)  
Dichgans, Martin  
Smith, Colin  
Werring, David  
Zedde, Marialuisa

### Update on brain atrophy

DeCarli, Charlie  
Ewers, Michael  
Jouvent, Eric (lead)  
Lebenberg, Jessica  
Pantoni, Leonardo  
Satizabal, Claudia

### Summary SVD score

Bae, Hee-Joon  
Brodthmann, Amy (lead)  
Field, Thalia  
Ganesh, Aravind  
Staals, Julie

### New and emerging features

Chen, Christopher (lead)  
Hilal, Saima  
Jochems, Angela  
Lam, Bonnie  
Smith, Colin  
van Veluw, Susanne  
Wang, Yilong

Structural quantitative imaging markers of SVD brain damage

de Leeuw, Frank-Erik (lead)

De Luca, Alberto

DeCarli, Charlie

Dewenter, Anna

Jochems, Angela

Schmidt, Reinhold

Markers of cerebrovascular function in SVD

Backes, Walter

Biessels, Geert Jan (lead)

Mok, Vincent

Thrippleton, Michael

Vemuri, Prashanti

Image acquisition

Doubal, Fergus

Frayne, Richard (lead)

Greenberg, Steve

Helmer, Karl

MacIntosh, Bradley

Vemuri, Prashanti

Image analysis

De Luca, Alberto

Duering, Marco

Kuijf, Hugo

Rost, Natalia (lead)

Rudilosso, Salvatore

Schirmer, Markus

## Literature search strategy

Based on a systematic literature search in PubMed, we aimed to evaluate the adoption of STRIVE-1 terminology, determine the success of STRIVE-1 in harmonising the SVD field and identify suboptimal terms. Specifically, we determined the number of manuscripts that reported on the main six SVD lesion types described in STRIVE-1 and assessed whether STRIVE terminology was adopted or whether non-preferred terminology was used in the title and/or abstract. Non-preferred variants were both retrieved from STRIVE-1 as well as determined by expert opinion. Specificity (i.e., relevance to the SVD field) was prioritised over sensitivity. Therefore, the following MeSH terms (all exploded) were added to the search code: "cerebral small vessel diseases", "dementia, vascular", "leukoaraiosis", "stroke", "magnetic resonance imaging" and "neuroimaging". Furthermore, results were restricted to human studies published in English. Additional MeSH terms were sometimes included to optimise the search results (i.e. MeSH terms "brain", "cerebral hemorrhage", and "tomography, x ray computed") as well as common abbreviations for several terms. The final combinations of terms for the main six SVD lesion types were reached after performing a series of searches in which different terms were added to or removed from the initial STRIVE-1 search code while evaluating whether key relevant papers were included based on expert opinion or recent systematic reviews. This was done for each lesion type separately. The exact search strategies for the main six SVD lesion types are given below. Searches were performed between 16 November and 2 December 2022. Except for "recent small subcortical infarcts" and "lacunes of presumed vascular origin", each member of the working group independently reviewed one SVD lesion type. Results are presented in **supplemental figure 1**.

### *Recent small subcortical infarct and lacune of presumed vascular origin*

((**recent small subcortical infarct**\*[Title/Abstract] OR **rssi**\*[Title/Abstract]) AND ("cerebral small vessel diseases"[MeSH Terms] OR "dementia, vascular"[MeSH Terms] OR "stroke"[MeSH Terms] OR "leukoaraiosis"[MeSH Terms] OR "brain"[MeSH Terms]) AND ("magnetic resonance imaging"[MeSH Terms] OR "tomography, x ray computed"[MeSH Terms] OR "neuroimaging"[MeSH Terms]) AND 2014/01/01:2021/12/31[Date - Publication]) AND ((humans[Filter]) AND (english[Filter]))

((**Lacune of presumed vascular origin**[Title/Abstract]) OR (**Lacunes of presumed vascular origin**[Title/Abstract])) AND ("cerebral small vessel diseases"[MeSH Terms] OR ("dementia, vascular"[MeSH Terms] OR ("stroke"[MeSH Terms] OR ("leukoaraiosis"[MeSH Terms] OR ("brain"[MeSH Terms])))) AND ("magnetic resonance imaging"[MeSH Terms] OR ("tomography, x ray computed"[MeSH Terms] OR ("neuroimaging"[MeSH Terms])))) AND (("2014/01/01"[Date - Publication] : "2021/12/31"[Date - Publication])) AND ((humans[Filter]) AND (english[Filter]))

For the non-preferred terms, the searches were otherwise identical, but the keyword “recent small subcortical infarct\*” was replaced with “lacunar infarct\*”, “subcortical infarct\*”, “lacune\*”, “silent brain infarct\*”, and “lacunar lesion\*”.

Of note, the non-preferred term "subcortical infarct" overlaps with the full names for CADASIL and CARASIL and the preferred term recent small subcortical infarct. Therefore, from the search results for the term "subcortical infarct", subsequently manuscripts were removed if they were part of the search results only due to mentioning the full names for CADASIL or CARASIL, or recent small subcortical infarct. In total, 169 manuscripts were removed. Similarly, due to overlap between proposed and non-preferred terms (i.e. "lacune of presumed vascular origin" and "lacune"), manuscripts using the proposed terminology in the title or abstract were subsequently removed from the search results for "lacune".

### *White matter hyperintensity of presumed vascular origin*

((**white matter hyperintens**\*[Title/Abstract]) OR (**WMH**[Title/Abstract])) AND ("cerebral small vessel diseases"[MeSH Terms] OR ("dementia, vascular"[MeSH Terms] OR ("stroke"[MeSH Terms] OR ("leukoaraiosis"[MeSH Terms])))) AND ("magnetic resonance imaging"[MeSH Terms] OR ("tomography, x ray computed"[MeSH Terms] OR ("neuroimaging"[MeSH Terms])))) AND (("2014/01/01"[Date - Publication] : "2021/12/31"[Date - Publication])) AND ((humans[Filter]) AND (english[Filter]))

For the non-preferred terms, the searches were otherwise identical, but the keyword “white matter hyperintens\*” was replaced by “leukoaraiosis”, “white matter lesion\*”, “white matter chang\*”, “leukoencephalopath\*”, “white matter disease\*”, “white matter damage\*” or “ischemic white matter disease\*”. Citations with leukoencephalopathy only appearing in the full names of CADASIL/CARASIL and studies of non-SVD-related conditions were excluded. The search results for ischaemic and ischemic white matter disease were combined.

Notably, the longer version “white matter hyperintensities of presumed vascular origin” has been rarely included in the titles and abstracts of published articles. However, it may have been used in the main text, where our search did not extend.

#### *Cerebral microbleed*

("cerebral microbleed"[Title/Abstract] OR "CMB"[Title/Abstract]) AND ("cerebral small vessel diseases"[MeSH Terms] OR "cerebral hemorrhage"[MeSH Terms] OR "leukoaraiosis"[MeSH Terms] OR "dementia, vascular"[MeSH Terms] OR stroke[MeSH Terms]) AND ("magnetic resonance imaging"[MeSH Terms] OR "tomography, x-ray computed"[MeSH Terms] OR "neuroimaging"[MeSH Terms]) AND (("2014/01/01"[Date - Publication] : "2021/12/31"[Date - Publication])) AND ((humans[Filter]) AND (english[Filter]))

Searching for "microbleed" alone included articles that used the proposed term "cerebral microbleed", though "microbleed" was sometimes used in the title, while the proposed term "cerebral microbleed" was used in the abstract. To account for this, the search for the term "microbleed" was modified to (NOT "cerebral microbleed"[Title/Abstract] OR "CMB"[Title/Abstract]) to determine the number of articles that used "microbleed" alone. Unlike "CMB", the abbreviation "MB" was not included in the search code as this would result in many irrelevant papers (e.g., on thrombolysis). Non-preferred terms "microhemorrhage" and its variant spelling "microhaemorrhage", and "dot-like hemosiderin" and its variant "dot-like haemosiderin" were also searched (identical search as above after the initial "AND").

#### *Perivascular space*

("Perivascular space"[Title/Abstract] OR "PVS"[Title/Abstract]) AND (("cerebral small vessel diseases"[MeSH Terms] OR ("dementia, vascular"[MeSH Terms] OR ("stroke"[MeSH Terms] OR ("leukoaraiosis"[MeSH Terms])) AND ("magnetic resonance imaging"[MeSH Terms] OR "neuroimaging"[MeSH Terms])) AND (("2014/01/01"[Date - Publication] : "2021/12/31"[Date - Publication])) AND ((humans[Filter]) AND (english[Filter]))

N = 9 manuscripts were deleted from the search results as PVS was used as a different abbreviation (e.g., pulmonary veins, prominent vessel sign, prominent veins). The non-preferred terms "Virchow Robin" or "Virchow-Robin", "type 3 lacune" and "état criblé", were searched using the same filters.

Of note, most papers that featured Virchow Robin space referred primarily to PVS and stated Virchow Robin space as an alternative name. Of the 186 abstracts using the term "perivascular space", 103 referred to PVS as "enlarged", "or dilated". These terms were noted as unsuitable in STRIVE-1 as although it is larger PVS that become visible on neuroimaging, the lack of understanding of the clinical implications of PVS size and the dependence of PVS visibility on the imaging used between different studies was deemed problematical.

#### *Brain atrophy*

((“brain atroph\*”[Title/Abstract] OR (“cerebral atroph\*” [Title/Abstract])) AND (("cerebral small vessel diseases"[MeSH Terms] OR ("dementia, vascular"[MeSH Terms] OR ("stroke"[MeSH Terms] OR ("leukoaraiosis"[MeSH Terms])) AND ("magnetic resonance imaging"[MeSH Terms] OR "neuroimaging"[MeSH Terms])) AND (("2014/01/01"[Date - Publication] : "2021/12/31"[Date - Publication])) AND ((humans[Filter]) AND (english[Filter]))

The less preferred term “brain volume” was searched for using the same filters, operationalised as “brain volum\*”[Title/Abstract] or “cerebral volum\*”[Title/Abstract].

*Summary SVD score*

((“cerebral small vessel disease” OR (“small vessel disease” AND (“brain” OR “cerebral”))) AND ("score" OR "multivariable" OR "markers" OR "total brain burden" OR "rating" OR "qualitative" OR "lacune" OR "lacunar infarct" OR "subcortical infarct" OR "subcortical stroke" OR "fazekas" OR "microbleed" OR "MARS" OR "BOMBS" OR "perivascular space" OR "EPVS score" OR "white matter hyperintensity") AND ((("2012/01/01"[Date - Publication] : "2020/12/31"[Date - Publication])))

*Microinfarct*

("microinfarct"[Title/Abstract] OR "microinfarction"[Title/Abstract] OR "microischemia"[Title/Abstract] OR "microvascular ischemia"[Title/Abstract] OR "microvascular infarct "[Title/Abstract])

## Supplemental text, tables and references

### Recent small subcortical infarcts on CT imaging

While MRI remains the most accurate technique to detect RSSI, urgent MRI is not always available, and CT-based techniques (non-contrast CT, with or without CT-angiography and CT-perfusion) are commonly used to assess patients presenting acutely with stroke. The sensitivity of CT for RSSI is low in the first hours after symptom-onset but might improve with CT-perfusion if it shows a focal small hypoperfusion in the relevant brain region (**supplemental figure 2**).<sup>8</sup>

### Incidental DWI-positive lesions

These emerging features have similar imaging characteristics to recent small subcortical infarcts (RSSI) when subcortical, show similar long-term outcomes to those of RSSI, and similar associations with increasing amounts of other cerebral small vessel disease (SVD) features as are seen with RSSI. Thus their prevalence is low in cross-sectional (older) population-based studies (0-1.5%),<sup>1-3</sup> but higher in patient cohorts with increasing symptomatology and SVD severity: patients with white matter hyperintensities of presumed vascular origin (WMH) and a history of lacunar stroke (8%), CADASIL (10.5%), probable cerebral amyloid angiopathy (CAA) (18%), or (sub)acute spontaneous intracerebral haemorrhage (ICH) (20%).<sup>4-6</sup>

Unlike RSSI, these incidental diffusion-weighted imaging-positive (DWI+) lesions are commonly not associated with discrete neurological (i.e., stroke-like) symptoms. They more commonly associate with subtle clinical manifestations, indicating that they are likely to be clinically relevant, perhaps representing ‘active’ vascular disease.<sup>1,7</sup>

Considering that the incidental DWI+ lesions are only visible on MRI up to 2-4 weeks after onset, the detection of only a few incidental DWI+ lesions on opportunistic MRI suggests the occurrence of these lesions may be higher relative to covert DWI+ lesions over time.<sup>5,8-10</sup>

Incidental DWI+ lesions may disappear, or evolve into WMH, lacunes, or CMI, thus partly explaining progression of these markers, further supporting an intrinsic small vessel abnormality as their underlying cause, similar to RSSI. However, as with RSSIs (**figure 1**), incidental DWI+ lesions may also reflect embolism, e.g., from carotid atherosclerotic stenosis awaiting revascularisation, or the heart.<sup>11,12</sup> As such, our understanding of the pathophysiology of these incidental DWI+ lesions remains incomplete.

Detection particularly of small incidental DWI+ lesions can be increased by using diffusion imaging with a high *b*-value (e.g.,  $b = 3000 \text{ s/mm}^2$ ) compared to a standard diffusion-weighting of  $b = 1000 \text{ s/mm}^2$ .<sup>13</sup>

### Non-intrinsic vascular causes of recent small subcortical infarcts

Infrequent causes of RSSI include thromboembolism from cardiac or extracranial, intracranial large artery and arteriolar branch atheroma<sup>14</sup> (**figure 1**) which may be difficult to differentiate when multiple potential causes are present. Having more than one RSSI concurrently, especially when in multiple arterial territories, may indicate an embolic cause, however concurrent RSSI may occur in severe SVD without an identifiable embolic source.<sup>15</sup> A RSSI and concurrent acute cortical infarct, RSSI with axial diameter larger than 2 cm when acute, suggest a non-intrinsic cause.<sup>14</sup> Tubular long RSSI with inferior limit close to perforator origin may suggest parent artery or branch atheroma (see *Intracranial atherosclerosis* below).<sup>16</sup>

## Perforating Arteries

Cerebral perforating arteries are small end-arteries which vascularise deep territories such as the basal ganglia, internal capsule, thalamus, and centrum semiovale white matter. Detection of these arteries and measurement of their blood flow velocity and pulsatility index have been shown to be feasible using ultra-high field MRI,<sup>80</sup> but techniques remain under development.<sup>81</sup>

## Venules

Venules, described as hypointense vessels on gradient echo and susceptibility-weighted imaging, have been analysed with visual rating scales and computational measures at 3T and 7T.<sup>36</sup> Several assessment tools have been proposed but remain to be standardised, and longitudinal studies are unavailable. Venous collagenosis may be an underlying pathology that changes venule appearance on MRI,<sup>29</sup> but there is as yet no direct corroboration with venule imaging.

## Intracranial atherosclerosis

Intracranial large artery disease has been associated with SVD and intracranial atherosclerosis and dolichoectasia (IAD),<sup>17</sup> the latter involving rarefaction of the tunica media elastic tissue and fragmentation of the internal elastic lamina.<sup>18</sup> IAD have been associated with RSSI, WMH, lacunes, cerebral microbleeds, atrophy and microinfarcts,<sup>16,17,19</sup> although it is unclear if these are direct associations and potentially causative, or co-associations due to shared risk factors, as seen with extracranial carotid stenosis.<sup>20</sup> One reason for questioning the directness of the relationship is that the RSSI often seems remote to the atheroma location,<sup>21,22</sup> with studies on this topic often not indicating if the RSSI was ipsilateral or contralateral to the IAD.

In addition to atheroma of parent arteries (usually middle cerebral artery [MCA] main stem or basilar artery) that might affect the basal perforating artery origins, atheroma may also occur in proximal perforating arteries, so called ‘branch atheromatous disease’ (BAD).<sup>23</sup> BAD is thought to be more likely in RSSI that are larger than 15 mm axial diameter and elongated or tubular in the infero-superior plane (e.g., 20 mm or more)<sup>23</sup> (**figure 1A**). However, the distinction in size between recent subcortical infarcts due to MCA atheroma or BAD and striatocapsular infarcts (due to MCA occlusion, either transient so too short to affect the superficial MCA territory, or where there are good collaterals that protect the superficial tissues) remains to be determined. Additionally, the proportion of tubular RSSI due to BAD versus intrinsic lipohyalinosis/fibrinoid necrosis is unknown. Advanced MRI sequences such as vessel wall imaging techniques with high-resolution MRI, ultrasmall superparamagnetic iron oxide (USPIO)-enhanced MRI to detect uptake into active atheroma, and 7T MRI are helping to visualise perforating artery structure, at least in the basal ganglia regions.<sup>24,25</sup>

## Quantitative susceptibility mapping for measuring iron deposition

Quantitative susceptibility mapping (QSM) measures susceptibility change including due to cerebral iron deposition.<sup>92</sup> Altered iron deposition in basal ganglia, confirmed histologically, has been reported in CADASIL.<sup>93</sup> In sporadic SVD, iron deposition associates independently with cognitive impairments, suggesting that mineral deposition may be an indicator of small vessel pathology,<sup>94</sup> although not consistently.<sup>95</sup> Most R2\* relaxometry methods use multiple gradient echo magnitude images. R2\*, however, does not fully reflect local tissue magnetic properties,<sup>92</sup> making interpretation of R2\* relaxometry difficult. Both methods also show increased tissue susceptibility in Alzheimer’s

Supplemental table 1. Advances in understanding of specific features and implications of traditional SVD features and in their detection and characterisation

Feature	Advance in understanding of morphology and implications			Notable features		Advances in detection or characterisation (image acquisition/analysis)
	Size limits	Aetiological hints	Long term change	Other characteristics	Miscellaneous	
<b>RSSI</b>	<p>A maximum axial diameter of 20mm is most often used for defining RSSI in clinical trials, sometimes up to 25 mm (on DWI) in the first hours after symptom onset,<sup>26</sup> if within the territory of a single perforating artery.</p> <p>Of note, the longest axis of RSSI may lay on different planes in some locations (coronal for lenticulostriate and thalamo-perforating arteries).</p>	<p>Other SVD markers are more frequent in anterior-circulation RSSI,<sup>27</sup> especially in deep white matter (corona radiata, centrum semiovale [CSO]) compared with basal ganglia, thalamus, or brainstem.<sup>27-30</sup></p> <p>Symptomatic RSSI are more likely to be located in/near main motor and sensory tracts than covert SVD lesions (lacunes, WMH).<sup>30</sup></p> <p>RSSI in basal ganglia are more likely to have a potential embolic source than those in the CSO.<sup>14</sup></p> <p>Larger RSSI are more frequent in basal ganglia and pons, associated with large artery atherosclerosis<sup>27</sup>.</p> <p>Branch atheromatous disease may cause RSSI, but small atherosclerotic plaques occluding perforating arteries are not visible on conventional MRI - new MRI vessel wall imaging techniques enhance their visibility.<sup>16,25,31,32</sup></p>	<p>About a third of RSSI evolve to some cavitation (leading to a lacune), a third will convert into a WMH, and a third will disappear on follow-up imaging.<sup>29,33-37</sup> The detection of small cavities or residual WMH depends on MRI field strength, slice thickness, image quality and contrast, etc.</p> <p>Predictors of cavitation are still scarcely investigated, but include ADC decrease, free water-corrected mean diffusivity, size of DWI hyperintensity, associated SVD lesions, serum neurofilament light chain, and occurrence of BBB alterations.<sup>33-36,38</sup></p>	<p>The shape of RSSI is classically described as round, ovoid, or tubular, but can be irregular, depending on the perforating artery distribution and level of occlusion.</p> <p>RSSI may disappear due to fogging (temporary loss of visibility of an infarct) and reappear (both on CT and MRI).<sup>39,40</sup></p>	<p>Lacunar syndrome has a moderate predictive value for RSSI, but the latter may be improved by adding other clinical predictors (NIHSS &lt;7).<sup>41</sup></p> <p>Covert lesions may appear on DWI in the follow-up of patients with severe SVD.<sup>6,8-10</sup> New small DWI+ lesions may be cortical, subcortical or both. The nature of these lesions is unclear and not necessarily related to perforating artery occlusions (see corresponding sections in the main manuscript).</p>	<p>CT perfusion enhances acute lesion visibility in patients with acute lacunar syndromes eligible for intravenous thrombolysis (<b>supplemental figure 2</b>). Sensitivity and specificity vary with vendor, acquisition, and processing parameters, especially for small and infratentorial infarcts.<sup>42-48</sup> Automatic detection tools are not available. Confirmation on follow-up MRI is recommended.</p> <p>Two small studies using CT perfusion and MR perfusion-weighted imaging<sup>49,50</sup> suggest presence of collateral retrograde blood flow through the capillary bed in RSSI.</p> <p>A small blooming effect on gradient-echo derived sequences is seen in up to 20% of RSSI.<sup>51,52</sup> The nature of this sign is controversial (i.e., deoxygenated haemoglobin trapped in clots occluding small perforators, blood-brain barrier leakage, small haemorrhagic transformation).</p>
<b>Lacune</b>	<p>Upper size limit of 15 mm rarely exceeded; size limit may vary according to the predominant location of lesions in the vascular tree depending on the perforating arteries.<sup>53</sup></p> <p>Lacunes are larger in the CSO and basal ganglia than in other locations.<sup>54</sup></p>	<p>After an incident lacune in presence of an identified source of embolism, the association of old lacunes and white-matter lesions are useful for implicating an underlying SVD.<sup>55</sup> However, the presence of an identified embolic source of previous cortical strokes do not exclude coexisting different pathogenetic processes.<sup>56</sup></p>	<p>Very few studies have explored longitudinal variations of lacunes; regression of lacunes over time was observed in &lt;4% of older persons with SVD.<sup>57</sup></p>	<p>Lacunes can develop at the edge of WMH suggesting undetermined factors of white matter vulnerability.<sup>58</sup></p> <p>Lacunes typically align their long axis with the course of perforating vessels,<sup>54</sup> but their shape may also be prolonged by tissue alterations, e.g., along white matter tracts.</p>	<p>See above predictors in the development of a lacune after RSSI</p>	<p>Lacunes counting can be obtained easily in presence of few lesions, methods for their evaluation should be fully validated.<sup>59</sup> Various methods are under development for their automatic quantification and learning algorithms are currently evaluated for their diagnostic performances.<sup>60</sup></p>



Feature	Advance in understanding of morphology and implications			Notable features		Advances in detection or characterisation (image acquisition/analysis)
	Size limits	Aetiological hints	Long term change	Other characteristics	Miscellaneous	
<b>WMH</b>	<p>No lower or upper size limits and WMH can be confluent or punctual.<sup>61</sup> Can also be characterised by concavity, fractal dimension, and eccentricity,<sup>62</sup> sphericity index,<sup>63</sup> compactness or curvedness.<sup>64</sup></p> <p>Potential Growth Index based on signal around the WMH boundary.<sup>65</sup></p> <p>Territories subdivided according to distance to ventricles (deep, periventricular); distance to cortex (sub-cortical and juxta-cortical);<sup>66</sup> basal ganglia, brainstem;<sup>67</sup> white matter tracts;<sup>68-70</sup> arterial territories (anterior, middle, and posterior);<sup>71</sup>; lobes<sup>72</sup></p> <p>WMH covariation pattern approach identified 4 components including 3 components surrounding the ventricles (posterior, frontal and dorsal PVWMH) and one component included the deep WMH and was located laterally to the other 3 components). Findings suggest that WMH follow age and disease-dependent regional distribution patterns<sup>73</sup></p>	<p>WMH in the anterior temporal poles, external capsules, and superior frontal regions are suggestive of CADASIL (sometimes CARASIL) and, compared to WMH in non-specific locations in CADASIL patients, their high-resolution imaging features suggest increased water content (edema).<sup>74</sup></p> <p>The corpus callosum is often involved in CADASIL, in contrast to sporadic SVD, which can sometimes lead to misdiagnosis with multiple sclerosis.<sup>75</sup></p> <p>Multiple subcortical WMH spots are more common in CAA compared to hypertensive arteriopathy; Peri-basal ganglia WMH are more common in hypertensive arteriopathy than in CAA.<sup>76</sup></p> <p>WMH distribution predominates in posterior regions in CAA.<sup>77,78</sup></p>	<p>WMH progression rates depend on the study population, with highest rates in SVD cohorts, intermediate rates in all stroke cohorts, and lower rates in the general population or patients with vascular risk factors. They are mostly influenced by age and baseline WMH volume.<sup>79</sup> Regression of WMH volume over time has also been reported in up to 20-25%.<sup>80-82</sup></p> <p>Longitudinal studies identified different categories of growth dynamic, including stagnant, growing, new and lost WMH.<sup>83,84</sup> FLAIR signal within the core of WMH was also shown to decrease in some lesions, providing further evidence for plausible regression of WMH.<sup>83</sup></p> <p>Antihypertensive treatment, especially with intensive BP lowering, is associated with a decreased progression of WMH.<sup>85-91</sup> Additional trials are underway (NCT02472028, NCT02913664).<sup>92</sup></p>	<p>WMH texture can be assessed using indices derived from WMH voxel intensity distribution, including run-length matrix or grey-level co-occurrence matrices.<sup>93,94</sup></p> <p>Studies using DTI and ASL have shown that WMH are surrounded by a region of more subtle injury,<sup>95,96</sup> referred to as WMH penumbra, at higher risk to convert into WMH over time,<sup>58,83</sup> suggesting that WM degeneration is a continuous process.</p> <p>Longitudinal studies using DCE and BOLD imaging showed that blood brain barrier and CVR at baseline were lower in NAWM regions converting into WMH over time.<sup>97-99</sup></p> <p>Recent radiomics studies extracted high-dimensional data, describing NAWM by its size, shape, histogram, and relationship between voxels predictive of WMH burden, building a robust image-based signature of the subvisible manifestations of WMH.<sup>100,101</sup></p>	<p>Measures of WMH volume have been reported to be associated with measures of cerebral blood flow (ASL, CT, DSC),<sup>102</sup> BBB (DCE),<sup>103</sup> diffusion imaging,<sup>104,105</sup> cerebrovascular reactivity (BOLD) in the healthy aging brain<sup>106</sup> and in SVD patients;<sup>107</sup> iron concentration and deposit (QSM, T2*/T1 mapping).<sup>108,109</sup></p> <p>Histopathological correlates of WMH include myelin pallor, vacuolation, decreased cellularity and dilated PVS for deep WMH and subependymal gliosis, abnormalities in myelin, axons and astroglia, sometimes with increased subependymal gliosis, for periventricular WMH,<sup>110</sup> venous collagenosis of the deep medullary veins<sup>111</sup></p>	<p>Although WMH volumetric assessment is now customary in research studies, a recent meta-analysis concluded that data on WMH volume in healthy adults appear to not be comparable across studies,<sup>112</sup> encouraging the development of automated WMH detection tools that provide reliable, reproducible and repeatable WMH measures.<sup>113</sup></p> <p>Novel automated methods for WMH detection have been developed using supervised and unsupervised learning algorithms. Supervised algorithms include k-nearest neighbours, large margin classifiers, multi-atlas segmentation, neural networks, feature filters, regression models, random forest, support vector machine.<sup>114,115</sup> Unsupervised algorithm comprise Kolmogorov-Smirnov test, partial-volume tissue segmentation, autoencoder segmentation auto-encoder, Gumbel or Fréchet histogram distributions, Limited One-Time Sampling Irregularity Map, segmentation method Bayesian Model Selection.<sup>114,115</sup></p>
<b>PVS</b>	<p>Maximum diameter usually 3 mm.<sup>116</sup> Lesions with a diameter &gt;3 mm are sometimes considered. Regardless of size PVS are fluid filled spaces with a signal identical to CSF; round, ovoid, or linear shape depending on slice direction; no hyperintense rim on T2w or FLAIR sequences.</p> <p>Careful differentiation from lacunes required, especially for PVS <math>\geq 3\text{mm}</math><sup>117</sup>, but also for PVS</p>	<p>Associations with age are strongest for PVS in basal ganglia.<sup>119</sup> High blood pressure is associated with PVS in basal ganglia but less strongly in white matter CSO).<sup>119</sup></p> <p>Association of PVS with WMH are more prominent for PVS in the basal ganglia than in the CSO.<sup>119</sup> Significant genetic correlation was observed</p>	<p>There are some indications that WMH seem to form around PVS.<sup>117,128,129</sup></p>	<p>7T MRI provides more detailed insight into the shape of PVS. PVS in basal ganglia frequently show calibre changes along their track. In the CSO, smoothly shaped PVS start a few millimetres below the cortex, converge and taper toward the ventricles.<sup>130</sup></p> <p>Computational PVS measures open new avenues for studying</p>	<p>PVS are already detectable at a very young age and were for instance described to be present in a healthy adolescent cohort, with a higher burden in men than in women in this age group.<sup>131</sup></p> <p>PVS burden appears to be highly heritable, especially in the white matter, suggesting that genetic studies could be useful tool to decipher underlying molecular mechanisms.<sup>120</sup></p>	<p>New visual rating scales have been developed, mostly based on predefined MRI slices (e.g., for PVS in white matter, 1 cm above the lateral ventricles; for PVS in basal ganglia, the slice showing the anterior commissure).<sup>132-134</sup></p> <p>Novel computational methods can now measure PVS count, volume, individual size, length, width, sphericity and orientation. Methods based primarily on image processing<sup>135-141</sup> have a limited</p>

Feature	Advance in understanding of morphology and implications			Notable features		Advances in detection or characterisation (image acquisition/analysis)
	<i>Size limits</i>	<i>Aetiological hints</i>	<i>Long term change</i>	<i>Other characteristics</i>	<i>Miscellaneous</i>	
	<3mm. Indeed, RSSI up to 10 mm size can resolve to leave a lacune with <2 mm. <sup>118</sup>	<p>between WMH and PVS in the basal ganglia only.<sup>120</sup></p> <p>PVS in hippocampus and basal ganglia are associated with intracerebral haemorrhage (ICH),<sup>121,122</sup> and lacunar stroke.<sup>123</sup></p> <p>Severe PVS in the CSO are frequent in patients with established CAA than controls,<sup>124,125</sup> and associated with recurrent ICH in CAA patients.<sup>126</sup> Juxtacortical PVS are associated with CAA severity.<sup>127</sup></p>		predictors and clinical significance of PVS shape.		interoperability. Methods based on deep learning <sup>142-146</sup> are very sensitive to the quality and amount of a priori knowledge available (and large and reliable learning sets require human operators to manually trace PVS on many subjects).

ADC=apparent diffusion coefficient. ASL=arterial spin labelling. BBB=blood-brain barrier. BOLD=blood oxygen level dependent imaging. CAA=cerebral amyloid angiopathy, CADASIL=cerebral autosomal dominant arteriopathy with subcortical infarcts and leukoencephalopathy. CARASIL=cerebral autosomal recessive arteriopathy with subcortical infarcts and leukoencephalopathy. CSO=centrum semiovale. CT=computed tomography. CVR=cerebrovascular reactivity. DCE=dynamic contrast enhanced. DTI=diffusion tensor imaging. FLAIR=fluid-attenuated inversion recovery. ICH=intracranial haemorrhage. NAWM=normal appearing white matter. PVS=perivascular space. PVWMH=periventricular white matter hyperintensity. QSM=quantitative susceptibility mapping. RSSI=recent small subcortical infarct. SVD=small vessel disease. WM=white matter. WMH=white matter hyperintensity.

Supplemental table 2: MRI markers of cerebrovascular function

	Method	Biological phenomenon	SVD related changes	Caveats, point of attention	Considerations on reporting
<b>MRI markers of tissue perfusion</b>	Dynamic susceptibility contrast (DSC)-MRI	Cerebral blood flow (CBF) (tissue perfusion)	CBF lower in SVD, but longitudinal associations and whether reduced CBF is cause or effect remain unclear.	Requires gadolinium contrast administration and advanced signal processing. Not fully quantitative. DSC is considered the clinical standard for brain perfusion MRI.	Perfusion MRI reporting recommendations are currently being prepared by the Open-Science Initiative for Perfusion Imaging ( <a href="https://osipi.org/OSIPI_CAPLEX/">https://osipi.org/OSIPI_CAPLEX/</a> ). Include details of contrast administration, MRI acquisition, image analysis and methods for generating ROIs.
	Dynamic Contrast Enhanced (DCE)-MRI			Requires gadolinium contrast administration and complex image processing.	
	Arterial spin labelling (ASL)			Low CNR in WM. Elevated arterial transit time may confound measurements.	
	BOLD or ASL MRI with hypercapnic challenge	Cerebrovascular reactivity: microvascular blood flow/volume change in response to CO <sub>2</sub> (regulated mostly at arteriolar level)	Low CVR associated with SVD severity and progression.	Require substantial ancillary equipment and patient cooperation. BOLD signal has complex dependence on biophysics properties. ASL signal has very low CNR in WM.	Harmonisation is at an early stage and reporting practice is varied. <sup>147</sup> We suggest to report CVR magnitude as the percent change in signal (BOLD) or CBF (ASL) per unit change in EtCO <sub>2</sub> [%/mmHg]. Include details of: MRI acquisition, image analysis and methods for generating ROIs.
<b>MRI markers of flow at vessel level</b>	Phase-contrast MRI carotid artery, primary arteries of circle of Willis; veins and venous sinuses; CSF.	Blood flow velocity, blood flow volume/time flow. <sup>148</sup> Flow pulsatility (possible indicator of arterial stiffness/compliance) Flow response to CO <sub>2</sub> can also be assessed	Flow/CBF lower and pulsatility index higher in SVD, <sup>149</sup> however longitudinal associations and cause or effect remain unclear	Flow and pulsatility measured in a particular artery (e.g., MCA) may be determined at up- or downstream levels.  Initially 2D, more complex 3D and 4D modelling of flow patterns emerging.	Report exact site of acquisition, preferably with images. Reports on pulsatility should include crude flow or velocity levels.
	Phase-contrast MRI perforating arteries basal ganglia, centrum semiovale	Blood flow velocity Flow velocity pulsatility (possible indicator of arterial stiffness/ compliance) Flow response to CO <sub>2</sub> can also be assessed	Indications that perforating artery flow is reduced and pulsatility index higher in SVD <sup>150,151</sup>	Flow, velocity and pulsatility measured in perforating arteries may be determined at up- or downstream levels.  Requires high field (e.g., 7T MRI) Confounded by partial volume effects, low CNR.	Emerging technique, requires further evaluation in terms of reproducibility, standardisation of post-processing <sup>152,153</sup>
<b>MRI markers of BBB function</b>	DCE-MRI	BBB disruption, permeability	Increased BBB leakage to contrast medium, and association with white matter hyperintensities and cognitive deficits	Technique is relatively prone to noise and other factors, requires further developments and independent means of validation.  Requires gadolinium contrast agent administration.	Report leakage rate (units: 1/min) and other quantities in specified brain regions. As the technique is prone to noise and novel developments are still emerging the reporting varies. Provide details of: contrast administration, MRI acquisition, T1 quantification, image analysis, pharmacokinetic modelling, and selection of ROIs, including vascular input function. <sup>154</sup>

	Method	Biological phenomenon	SVD related changes	Caveats, point of attention	Considerations on reporting
	ASL-based techniques (e.g., diffusion-prepared ASL, T2W-ASL)	Water exchange across blood-brain interface	Exchange decreased with ageing, <sup>155</sup> but not investigated yet in SVD.	Different techniques are currently under development.  Water exchange is a natural transport phenomenon and experiences only a partial barrier at the blood-brain interface	Report exchange rate of water from blood to brain (units: 1/min) and, if possible, the permeability surface area product to water (units: mL blood or extracellular fluid/mL tissue/min) and other quantities in specified brain regions. Include details of: MRI acquisition, use of contrast agent, image processing and generation of ROIs. <sup>156</sup>
	Dynamic Glucose Enhanced (DGE) MRI	Glucose uptake through GLUT1 transporter protein	Reduced glucose uptake in Alzheimer's, but not yet investigated in SVD	Emerging technique, which requires advanced MRI hardware to generate high power off-resonance pulses to selectively saturate hydroxyl protons in D-glucose that exchange with water and sufficient spectral separation of the saturation offset frequency from the water resonance, for which ultra-high field (e.g., 7T) is beneficial	Method is at an early stage in development and has not been applied to SVD yet. Relative signal changes are reported. <sup>157,158</sup>

ASL=arterial spin labelling. BBB=blood-brain barrier. BOLD=blood oxygen level dependent. CBF=cerebral blood flow. CNR=contrast-to-noise ratio. CVR=cerebrovascular reactivity. DW-ASL=diffusion-weighted ASL. DCE=dynamic contrast enhanced. EtCO<sub>2</sub>=end-tidal CO<sub>2</sub> partial pressure. GLUT1=glucose transporter 1. MCA=middle cerebral artery. ROI=region of interest. SVD=small vessel disease. T2W=T2-weighted. WM=white matter.

### Supplemental references

1. Hilal S, Baaij LGA, de Groot M, et al. Prevalence and clinical relevance of diffusion-weighted imaging lesions: The Rotterdam study. *Neurology* 2019; **93**(11): e1058-e67.
2. Saini M, Suministrado MS, Hilal S, et al. Prevalence and Risk Factors of Acute Incidental Infarcts. *Stroke* 2015; **46**(10): 2722-7.
3. Batool S, O'Donnell M, Sharma M, et al. Incidental magnetic resonance diffusion-weighted imaging-positive lesions are rare in neurologically asymptomatic community-dwelling adults. *Stroke* 2014; **45**(7): 2115-7.
4. Boulanger M, Schneckenburger R, Join-Lambert C, et al. Diffusion-Weighted Imaging Hyperintensities in Subtypes of Acute Intracerebral Hemorrhage. *Stroke* 2018; STROKEAHA118021407.
5. van Veluw SJ, Lauer A, Charidimou A, et al. Evolution of DWI lesions in cerebral amyloid angiopathy: Evidence for ischemia. *Neurology* 2017; **89**(21): 2136-42.
6. O'Sullivan M, Rich PM, Barrick TR, Clark CA, Markus HS. Frequency of subclinical lacunar infarcts in ischemic leukoaraiosis and cerebral autosomal dominant arteriopathy with subcortical infarcts and leukoencephalopathy. *AJNR Am J Neuroradiol* 2003; **24**(7): 1348-54.
7. Ferro DA, van den Brink H, Exalto LG, et al. Clinical relevance of acute cerebral microinfarcts in vascular cognitive impairment. *Neurology* 2019; **92**(14): e1558-e66.
8. Wiegertjes K, Ter Telgte A, Oliveira PB, et al. The role of small diffusion-weighted imaging lesions in cerebral small vessel disease. *Neurology* 2019; **93**(17): e1627-e34.
9. Ter Telgte A, Wiegertjes K, Gesierich B, et al. Contribution of acute infarcts to cerebral small vessel disease progression. *Ann Neurol* 2019; **86**(4): 582-92.
10. Conklin J, Silver FL, Mikulis DJ, Mandell DM. Are acute infarcts the cause of leukoaraiosis? Brain mapping for 16 consecutive weeks. *Ann Neurol* 2014; **76**(6): 899-904.
11. Rots ML, Timmerman N, de Kleijn DPV, et al. Magnetic Resonance Imaging Identified Brain Ischaemia in Symptomatic Patients Undergoing Carotid Endarterectomy Is Related to Histologically Apparent Intraplaque Haemorrhage. *Eur J Vasc Endovasc Surg* 2019; **58**(6): 796-804.
12. Ay H, Oliveira-Filho J, Buonanno FS, et al. Diffusion-weighted imaging identifies a subset of lacunar infarction associated with embolic source. *Stroke* 1999; **30**(12): 2644-50.
13. Lettau M, Laible M. 3-T high-b-value diffusion-weighted MR imaging in hyperacute ischemic stroke. *J Neuroradiol* 2013; **40**(3): 149-57.
14. Del Bene A, Makin SD, Doubal FN, Inzitari D, Wardlaw JM. Variation in risk factors for recent small subcortical infarcts with infarct size, shape, and location. *Stroke* 2013; **44**(11): 3000-6.
15. Wardlaw JM, Smith EE, Biessels GJ, et al. Neuroimaging standards for research into small vessel disease and its contribution to ageing and neurodegeneration. *Lancet Neurol* 2013; **12**(8): 822-38.
16. Jiang S, Cao T, Yan Y, et al. Lenticulostriate artery combined with neuroimaging markers of cerebral small vessel disease differentiate the pathogenesis of recent subcortical infarction. *J Cereb Blood Flow Metab* 2021; **41**(8): 2105-15.
17. Zhai FF, Yan S, Li ML, et al. Intracranial Arterial Dolichoectasia and Stenosis: Risk Factors and Relation to Cerebral Small Vessel Disease. *Stroke* 2018; **49**(5): 1135-40.
18. Pico F, Labreuche J, Amarenco P. Pathophysiology, presentation, prognosis, and management of intracranial arterial dolichoectasia. *Lancet Neurol* 2015; **14**(8): 833-45.
19. Zwartbol MH, van der Kolk AG, Kuijff HJ, et al. Intracranial vessel wall lesions on 7T MRI and MRI features of cerebral small vessel disease: The SMART-MR study. *J Cereb Blood Flow Metab* 2021; **41**(6): 1219-28.
20. Wardlaw JM, Allerhand M, Doubal FN, et al. Vascular risk factors, large-artery atheroma, and brain white matter hyperintensities. *Neurology* 2014; **82**(15): 1331-8.

21. Thijs V, Grittner U, Fazekas F, et al. Dolichoectasia and Small Vessel Disease in Young Patients With Transient Ischemic Attack and Stroke. *Stroke* 2017; **48**(9): 2361-7.
22. Park JM, Koo JS, Kim BK, et al. Vertebrobasilar dolichoectasia as a risk factor for cerebral microbleeds. *Eur J Neurol* 2013; **20**(5): 824-30.
23. Nakase T, Yoshioka S, Sasaki M, Suzuki A. Clinical evaluation of lacunar infarction and branch atheromatous disease. *J Stroke Cerebrovasc Dis* 2013; **22**(4): 406-12.
24. Xu W. High-resolution MRI of intracranial large artery diseases: how to use it in clinical practice? *Stroke Vasc Neurol* 2019; **4**(2): 102-4.
25. Zhang Z, Fan Z, Kong Q, et al. Visualization of the lenticulostriate arteries at 3T using black-blood T1-weighted intracranial vessel wall imaging: comparison with 7T TOF-MRA. *Eur Radiol* 2019; **29**(3): 1452-9.
26. Gattringer T, Pinter D, Enzinger C, et al. Serum neurofilament light is sensitive to active cerebral small vessel disease. *Neurology* 2017; **89**(20): 2108-14.
27. Eppinger S, Gattringer T, Nachbaur L, et al. Are morphologic features of recent small subcortical infarcts related to specific etiologic aspects? *Ther Adv Neurol Disord* 2019; **12**: 1756286419835716.
28. Rudilosso S, Mena L, Esteller D, et al. Higher Cerebral Small Vessel Disease Burden in Patients with White Matter Recent Small Subcortical Infarcts. *J Stroke Cerebrovasc Dis* 2021; **30**(7): 105824.
29. Hong H, Zhang R, Yu X, et al. Factors Associated With the Occurrence and Evolution of Recent Small Subcortical Infarcts (RSSIs) in Different Locations. *Front Aging Neurosci* 2020; **12**: 264.
30. Valdes Hernandez MDC, Grimsley-Moore T, Sakka E, et al. Lacunar Stroke Lesion Extent and Location and White Matter Hyperintensities Evolution 1 Year Post-lacunar Stroke. *Front Neurol* 2021; **12**: 640498.
31. Jiang S, Yan Y, Yang T, et al. Plaque Distribution Correlates With Morphology of Lenticulostriate Arteries in Single Subcortical Infarctions. *Stroke* 2020; **51**(9): 2801-9.
32. Sun LL, Li ZH, Tang WX, et al. High resolution magnetic resonance imaging in pathogenesis diagnosis of single lenticulostriate infarction with nonstenotic middle cerebral artery, a retrospective study. *BMC Neurol* 2018; **18**(1): 51.
33. Gattringer T, Valdes Hernandez M, Heye A, et al. Predictors of Lesion Cavitation After Recent Small Subcortical Stroke. *Transl Stroke Res* 2020; **11**(3): 402-11.
34. Kwon HS, Cho AH, Lee MH, et al. Evolution of acute lacunar lesions in terms of size and shape: a PICASSO sub-study. *J Neurol* 2019; **266**(3): 766-72.
35. Duering M, Adam R, Wollenweber FA, et al. Within-lesion heterogeneity of subcortical DWI lesion evolution, and stroke outcome: A voxel-based analysis. *J Cereb Blood Flow Metab* 2020; **40**(7): 1482-91.
36. Pinter D, Gattringer T, Enzinger C, et al. Longitudinal MRI dynamics of recent small subcortical infarcts and possible predictors. *J Cereb Blood Flow Metab* 2019; **39**(9): 1669-77.
37. Lee KJ, Jung H, Oh YS, Lim EY, Cho AH. The Fate of Acute Lacunar Lesions in Terms of Shape and Size. *J Stroke Cerebrovasc Dis* 2017; **26**(6): 1254-7.
38. Du M, Bai H, Chen J, et al. Magnetic resonance imaging and risk factors for progression of lacunar infarct lesions in Chinese patients. *Neuroradiology* 2020; **62**(2): 161-6.
39. O'Brien P, Sellar RJ, Wardlaw JM. Fogging on T2-weighted MR after acute ischaemic stroke: how often might this occur and what are the implications? *Neuroradiology* 2004; **46**(8): 635-41.
40. Skriver EB, Olsen TS. Repeated computed tomography in lacunar infarcts of the brain. *Acta Radiol* 1989; **30**(1): 1-6.
41. Arba F, Mair G, Phillips S, Sandercock P, Wardlaw JM, Third International Stroke Trial C. Improving Clinical Detection of Acute Lacunar Stroke: Analysis From the IST-3. *Stroke* 2020; **51**(5): 1411-8.
42. Rudilosso S, Urra X, San Roman L, et al. Perfusion Deficits and Mismatch in Patients with Acute Lacunar Infarcts Studied with Whole-Brain CT Perfusion. *AJNR Am J Neuroradiol* 2015; **36**(8): 1407-12.

43. Das T, Settecase F, Boulos M, et al. Multimodal CT provides improved performance for lacunar infarct detection. *AJNR Am J Neuroradiol* 2015; **36**(6): 1069-75.
44. Benson JC, Payabvash S, Mortazavi S, et al. CT Perfusion in Acute Lacunar Stroke: Detection Capabilities Based on Infarct Location. *AJNR Am J Neuroradiol* 2016; **37**(12): 2239-44.
45. Tan MY, Singhal S, Ma H, et al. Examining Subcortical Infarcts in the Era of Acute Multimodality CT Imaging. *Front Neurol* 2016; **7**: 220.
46. Cao W, Yassi N, Sharma G, et al. Diagnosing acute lacunar infarction using CT perfusion. *J Clin Neurosci* 2016; **29**: 70-2.
47. Garcia-Esperon C, Visser M, Churilov L, et al. Role of Computed Tomography Perfusion in Identification of Acute Lacunar Stroke Syndromes. *Stroke* 2021; **52**(1): 339-43.
48. Bill O, Inacio NM, Lambrou D, et al. Focal Hypoperfusion in Acute Ischemic Stroke Perfusion CT: Clinical and Radiologic Predictors and Accuracy for Infarct Prediction. *AJNR Am J Neuroradiol* 2019; **40**(3): 483-9.
49. Rudilosso S, Laredo C, Mancosu M, et al. Cerebral perfusion and compensatory blood supply in patients with recent small subcortical infarcts. *J Cereb Blood Flow Metab* 2019; **39**(7): 1326-35.
50. Forster A, Murle B, Bohme J, et al. Perfusion-weighted imaging and dynamic 4D angiograms for the estimation of collateral blood flow in lacunar infarction. *J Cereb Blood Flow Metab* 2016; **36**(10): 1744-54.
51. Wardlaw JM, Dennis MS, Warlow CP, Sandercock PA. Imaging appearance of the symptomatic perforating artery in patients with lacunar infarction: occlusion or other vascular pathology? *Ann Neurol* 2001; **50**(2): 208-15.
52. Rudilosso S, Olivera M, Esteller D, et al. Susceptibility Vessel Sign in Deep Perforating Arteries in Patients with Recent Small Subcortical Infarcts. *J Stroke Cerebrovasc Dis* 2021; **30**(1): 105415.
53. Moreton FC, During M, Phan T, et al. Arterial branching and basal ganglia lacunes: A study in pure small vessel disease. *Eur Stroke J* 2017; **2**(3): 264-71.
54. Gesierich B, Duchesnay E, Jouvent E, et al. Features and Determinants of Lacune Shape: Relationship With Fiber Tracts and Perforating Arteries. *Stroke* 2016; **47**(5): 1258-64.
55. Park YS, Chung PW, Kim YB, et al. Small deep infarction in patients with atrial fibrillation: evidence of lacunar pathogenesis. *Cerebrovasc Dis* 2013; **36**(3): 205-10.
56. Sharobeam A, Churilov L, Parsons M, Donnan GA, Davis SM, Yan B. Patterns of Infarction on MRI in Patients With Acute Ischemic Stroke and Cardio-Embolic: A Systematic Review and Meta-Analysis. *Front Neurol* 2020; **11**: 606521.
57. van Leijssen EM, Bergkamp MI, van Uden IW, et al. Cognitive consequences of regression of cerebral small vessel disease. *Eur Stroke J* 2019; **4**(1): 85-9.
58. Duering M, Csanadi E, Gesierich B, et al. Incident lacunes preferentially localize to the edge of white matter hyperintensities: insights into the pathophysiology of cerebral small vessel disease. *Brain* 2013; **136**(Pt 9): 2717-26.
59. Ling Y, Chabriat H. Incident cerebral lacunes: A review. *J Cereb Blood Flow Metab* 2020; **40**(5): 909-21.
60. Duan Y, Shan W, Liu L, et al. Primary Categorizing and Masking Cerebral Small Vessel Disease Based on "Deep Learning System". *Front Neuroinform* 2020; **14**: 17.
61. Das AS, Regenhardt RW, Vernooij MW, Blacker D, Charidimou A, Viswanathan A. Asymptomatic Cerebral Small Vessel Disease: Insights from Population-Based Studies. *J Stroke* 2019; **21**(2): 121-38.
62. Ghaznawi R, Geerlings MI, Jaarsma-Coes M, Hendrikse J, de Bresser J, Group UC-SS. Association of White Matter Hyperintensity Markers on MRI and Long-term Risk of Mortality and Ischemic Stroke: The SMART-MR Study. *Neurology* 2021; **96**(17): e2172-e83.
63. Han JW, Lee H, Lee S, et al. Association of the Irregular 3-Dimensional Shape of White Matter Hyperintensities with Cognitive Function. *Eur Neurol* 2021; **84**(4): 280-7.

64. de Bresser J, Kuijf HJ, Zaanen K, et al. White matter hyperintensity shape and location feature analysis on brain MRI; proof of principle study in patients with diabetes. *Sci Rep* 2018; **8**(1): 1893.
65. Gwo CY, Zhu DC, Zhang R. Brain White Matter Hyperintensity Lesion Characterization in T2 Fluid-Attenuated Inversion Recovery Magnetic Resonance Images: Shape, Texture, and Potential Growth. *Front Neurosci* 2019; **13**: 353.
66. Dobrynina LA, Suslina AD, Gubanov MV, et al. White matter hyperintensity in different migraine subtypes. *Sci Rep* 2021; **11**(1): 10881.
67. Medrano-Martorell S, Capellades J, Jimenez-Conde J, et al. Risk factors analysis according to regional distribution of white matter hyperintensities in a stroke cohort. *Eur Radiol* 2022; **32**(1): 272-80.
68. Duering M, Gesierich B, Seiler S, et al. Strategic white matter tracts for processing speed deficits in age-related small vessel disease. *Neurology* 2014; **82**(22): 1946-50.
69. Seiler S, Fletcher E, Hassan-Ali K, et al. Cerebral tract integrity relates to white matter hyperintensities, cortex volume, and cognition. *Neurobiol Aging* 2018; **72**: 14-22.
70. Habes M, Erus G, Toledo JB, et al. Regional tract-specific white matter hyperintensities are associated with patterns to aging-related brain atrophy via vascular risk factors, but also independently. *Alzheimers Dement (Amst)* 2018; **10**: 278-84.
71. Schirmer MD, Giese AK, Fotiadis P, et al. Spatial Signature of White Matter Hyperintensities in Stroke Patients. *Front Neurol* 2019; **10**: 208.
72. Brugulat-Serrat A, Salvado G, Sudre CH, et al. Patterns of white matter hyperintensities associated with cognition in middle-aged cognitively healthy individuals. *Brain Imaging Behav* 2020; **14**(5): 2012-23.
73. Habes M, Sotiras A, Erus G, et al. White matter lesions: Spatial heterogeneity, links to risk factors, cognition, genetics, and atrophy. *Neurology* 2018; **91**(10): e964-e75.
74. De Guio F, Vignaud A, Chabriat H, Jouvent E. Different types of white matter hyperintensities in CADASIL: Insights from 7-Tesla MRI. *J Cereb Blood Flow Metab* 2018; **38**(9): 1654-63.
75. Mancuso M, Arnold M, Bersano A, et al. Monogenic cerebral small-vessel diseases: diagnosis and therapy. Consensus recommendations of the European Academy of Neurology. *Eur J Neurol* 2020; **27**(6): 909-27.
76. Charidimou A, Boulouis G, Haley K, et al. White matter hyperintensity patterns in cerebral amyloid angiopathy and hypertensive arteriopathy. *Neurology* 2016; **86**(6): 505-11.
77. Thanprasertsuk S, Martinez-Ramirez S, Pontes-Neto OM, et al. Posterior white matter disease distribution as a predictor of amyloid angiopathy. *Neurology* 2014; **83**(9): 794-800.
78. Ii Y, Ishikawa H, Matsuyama H, et al. Hypertensive Arteriopathy and Cerebral Amyloid Angiopathy in Patients with Cognitive Decline and Mixed Cerebral Microbleeds. *J Alzheimers Dis* 2020; **78**(4): 1765-74.
79. Brown R, Low A, Markus HS. Rate of, and risk factors for, white matter hyperintensity growth: a systematic review and meta-analysis with implications for clinical trial design. *J Neurol Neurosurg Psychiatry* 2021; **92**(12): 1271-7.
80. Al-Janabi OM, Bauer CE, Goldstein LB, et al. White Matter Hyperintensity Regression: Comparison of Brain Atrophy and Cognitive Profiles with Progression and Stable Groups. *Brain Sci* 2019; **9**(7).
81. Wardlaw JM, Valdes Hernandez MC, Munoz-Maniega S. What are white matter hyperintensities made of? Relevance to vascular cognitive impairment. *J Am Heart Assoc* 2015; **4**(6): 001140.
82. van Leijssen EMC, de Leeuw FE, Tuladhar AM. Disease progression and regression in sporadic small vessel disease-insights from neuroimaging. *Clin Sci (Lond)* 2017; **131**(12): 1191-206.
83. Maillard P, Fletcher E, Lockhart SN, et al. White matter hyperintensities and their penumbra lie along a continuum of injury in the aging brain. *Stroke* 2014; **45**(6): 1721-6.
84. de Groot M, Verhaaren BF, de Boer R, et al. Changes in normal-appearing white matter precede development of white matter lesions. *Stroke* 2013; **44**(4): 1037-42.
85. Group SMIfSR, Nasrallah IM, Pajewski NM, et al. Association of Intensive vs Standard Blood Pressure Control With Cerebral White Matter Lesions. *JAMA* 2019; **322**(6): 524-34.



86. White WB, Wakefield DB, Moscufo N, et al. Effects of Intensive Versus Standard Ambulatory Blood Pressure Control on Cerebrovascular Outcomes in Older People (INFINITY). *Circulation* 2019; **140**(20): 1626-35.
87. Wardlaw JM, DeBette S, Jokinen H, et al. ESO Guideline on covert cerebral small vessel disease. *Eur Stroke J* 2021; **6**(2): IV.
88. Murray AM, Hsu FC, Williamson JD, et al. ACCORDION MIND: results of the observational extension of the ACCORD MIND randomised trial. *Diabetologia* 2017; **60**(1): 69-80.
89. van Dalen JW, Moll van Charante EP, Caan MWA, et al. Effect of Long-Term Vascular Care on Progression of Cerebrovascular Lesions: Magnetic Resonance Imaging Substudy of the PreDIVA Trial (Prevention of Dementia by Intensive Vascular Care). *Stroke* 2017; **48**(7): 1842-8.
90. Williamson JD, Launer LJ, Bryan RN, et al. Cognitive function and brain structure in persons with type 2 diabetes mellitus after intensive lowering of blood pressure and lipid levels: a randomized clinical trial. *JAMA Intern Med* 2014; **174**(3): 324-33.
91. de Havenon A, Majersik JJ, Tirschwell DL, McNally JS, Stoddard G, Rost NS. Blood pressure, glycemic control, and white matter hyperintensity progression in type 2 diabetics. *Neurology* 2019; **92**(11): e1168-e75.
92. Moroni F, Ammirati E, Rocca MA, Filippi M, Magnoni M, Camici PG. Cardiovascular disease and brain health: Focus on white matter hyperintensities. *Int J Cardiol Heart Vasc* 2018; **19**: 63-9.
93. Ithapu V, Singh V, Lindner C, et al. Extracting and summarizing white matter hyperintensities using supervised segmentation methods in Alzheimer's disease risk and aging studies. *Hum Brain Mapp* 2014; **35**(8): 4219-35.
94. Leite M, Rittner L, Appenzeller S, Ruocco HH, Lotufo R. Etiology-based classification of brain white matter hyperintensity on magnetic resonance imaging. *J Med Imaging (Bellingham)* 2015; **2**(1): 014002.
95. Promjunyakul NO, Lahna DL, Kaye JA, et al. Comparison of cerebral blood flow and structural penumbras in relation to white matter hyperintensities: A multi-modal magnetic resonance imaging study. *J Cereb Blood Flow Metab* 2016; **36**(9): 1528-36.
96. Maillard P, Fletcher E, Harvey D, et al. White matter hyperintensity penumbra. *Stroke* 2011; **42**(7): 1917-22.
97. Kerkhofs D, Wong SM, Zhang E, et al. Baseline Blood-Brain Barrier Leakage and Longitudinal Microstructural Tissue Damage in the Periphery of White Matter Hyperintensities. *Neurology* 2021; **96**(17): e2192-e200.
98. Sam K, Crawley AP, Conklin J, et al. Development of White Matter Hyperintensity Is Preceded by Reduced Cerebrovascular Reactivity. *Ann Neurol* 2016; **80**(2): 277-85.
99. Maillard P, Carmichael O, Harvey D, et al. FLAIR and diffusion MRI signals are independent predictors of white matter hyperintensities. *AJNR Am J Neuroradiol* 2013; **34**(1): 54-61.
100. Bretzner M, Bonkhoff AK, Schirmer MD, et al. MRI Radiomic Signature of White Matter Hyperintensities Is Associated With Clinical Phenotypes. *Front Neurosci* 2021; **15**: 691244.
101. Shao Y, Chen Z, Ming S, et al. Predicting the Development of Normal-Appearing White Matter With Radiomics in the Aging Brain: A Longitudinal Clinical Study. *Front Aging Neurosci* 2018; **10**: 393.
102. Stewart CR, Stringer MS, Shi Y, Thrippleton MJ, Wardlaw JM. Associations Between White Matter Hyperintensity Burden, Cerebral Blood Flow and Transit Time in Small Vessel Disease: An Updated Meta-Analysis. *Front Neurol* 2021; **12**: 647848.
103. Freeze WM, Jacobs HIL, de Jong JJ, et al. White matter hyperintensities mediate the association between blood-brain barrier leakage and information processing speed. *Neurobiol Aging* 2020; **85**: 113-22.
104. Maillard P, Mitchell GF, Himali JJ, et al. Aortic Stiffness, Increased White Matter Free Water, and Altered Microstructural Integrity: A Continuum of Injury. *Stroke* 2017; **48**(6): 1567-73.
105. Duering M, Finsterwalder S, Baykara E, et al. Free water determines diffusion alterations and clinical status in cerebral small vessel disease. *Alzheimers Dement* 2018; **14**(6): 764-74.

106. Scarapicchia V, Garcia-Barrera M, MacDonald S, Gawryluk JR. Resting State BOLD Variability Is Linked to White Matter Vascular Burden in Healthy Aging but Not in Older Adults With Subjective Cognitive Decline. *Front Hum Neurosci* 2019; **13**: 429.
107. Blair GW, Thrippleton MJ, Shi Y, et al. Intracranial hemodynamic relationships in patients with cerebral small vessel disease. *Neurology* 2020; **94**(21): e2258-e69.
108. Valdes Hernandez M, Allerhand M, Glatz A, et al. Do white matter hyperintensities mediate the association between brain iron deposition and cognitive abilities in older people? *Eur J Neurol* 2016; **23**(7): 1202-9.
109. Bauer CE, Zachariou V, Seago E, Gold BT. White Matter Hyperintensity Volume and Location: Associations With WM Microstructure, Brain Iron, and Cerebral Perfusion. *Front Aging Neurosci* 2021; **13**: 617947.
110. Humphreys CA, Smith C, Wardlaw JM. Correlations in post-mortem imaging-histopathology studies of sporadic human cerebral small vessel disease: A systematic review. *Neuropathol Appl Neurobiol* 2021; **47**(7): 910-30.
111. Keith J, Gao FQ, Noor R, et al. Collagenosis of the Deep Medullary Veins: An Underrecognized Pathologic Correlate of White Matter Hyperintensities and Periventricular Infarction? *J Neuropathol Exp Neurol* 2017; **76**(4): 299-312.
112. Melazzini L, Vitali P, Olivieri E, et al. White Matter Hyperintensities Quantification in Healthy Adults: A Systematic Review and Meta-Analysis. *J Magn Reson Imaging* 2021; **53**(6): 1732-43.
113. Lu H, Kashani AH, Arfanakis K, et al. MarkVCID cerebral small vessel consortium: II. Neuroimaging protocols. *Alzheimers Dement* 2021; **17**(4): 716-25.
114. Caligiuri ME, Perrotta P, Augimeri A, Rocca F, Quattrone A, Cherubini A. Automatic Detection of White Matter Hyperintensities in Healthy Aging and Pathology Using Magnetic Resonance Imaging: A Review. *Neuroinformatics* 2015; **13**(3): 261-76.
115. Balakrishnan R, Valdes Hernandez MDC, Farrall AJ. Automatic segmentation of white matter hyperintensities from brain magnetic resonance images in the era of deep learning and big data - A systematic review. *Comput Med Imaging Graph* 2021; **88**: 101867.
116. Hernandez Mdel C, Piper RJ, Wang X, Deary IJ, Wardlaw JM. Towards the automatic computational assessment of enlarged perivascular spaces on brain magnetic resonance images: a systematic review. *J Magn Reson Imaging* 2013; **38**(4): 774-85.
117. Ding J, Sigurdsson S, Jonsson PV, et al. Large Perivascular Spaces Visible on Magnetic Resonance Imaging, Cerebral Small Vessel Disease Progression, and Risk of Dementia: The Age, Gene/Environment Susceptibility-Reykjavik Study. *JAMA Neurol* 2017; **74**(9): 1105-12.
118. Wardlaw JM, Benveniste H, Nedergaard M, et al. Perivascular spaces in the brain: anatomy, physiology and pathology. *Nat Rev Neurol* 2020; **16**(3): 137-53.
119. Francis F, Ballerini L, Wardlaw JM. Perivascular spaces and their associations with risk factors, clinical disorders and neuroimaging features: A systematic review and meta-analysis. *Int J Stroke* 2019; **14**(4): 359-71.
120. Duperron MG, Tzourio C, Sargurupremraj M, et al. Burden of Dilated Perivascular Spaces, an Emerging Marker of Cerebral Small Vessel Disease, Is Highly Heritable. *Stroke* 2018; **49**(2): 282-7.
121. Duperron MG, Tzourio C, Schilling S, et al. High dilated perivascular space burden: a new MRI marker for risk of intracerebral hemorrhage. *Neurobiol Aging* 2019; **84**: 158-65.
122. Charidimou A, Boulouis G, Pasi M, et al. MRI-visible perivascular spaces in cerebral amyloid angiopathy and hypertensive arteriopathy. *Neurology* 2017; **88**(12): 1157-64.
123. Doubal FN, MacLulich AM, Ferguson KJ, Dennis MS, Wardlaw JM. Enlarged perivascular spaces on MRI are a feature of cerebral small vessel disease. *Stroke* 2010; **41**(3): 450-4.
124. Martinez-Ramirez S, van Rooden S, Charidimou A, et al. Perivascular Spaces Volume in Sporadic and Hereditary (Dutch-Type) Cerebral Amyloid Angiopathy. *Stroke* 2018; **49**(8): 1913-9.

125. Charidimou A, Jaunmuktane Z, Baron JC, et al. White matter perivascular spaces: an MRI marker in pathology-proven cerebral amyloid angiopathy? *Neurology* 2014; **82**(1): 57-62.
126. Boulouis G, Charidimou A, Pasi M, et al. Hemorrhage recurrence risk factors in cerebral amyloid angiopathy: Comparative analysis of the overall small vessel disease severity score versus individual neuroimaging markers. *J Neurol Sci* 2017; **380**: 64-7.
127. van Veluw SJ, Biessels GJ, Bouvy WH, et al. Cerebral amyloid angiopathy severity is linked to dilation of juxtacortical perivascular spaces. *J Cereb Blood Flow Metab* 2016; **36**(3): 576-80.
128. Wardlaw JM, Smith C, Dichgans M. Small vessel disease: mechanisms and clinical implications. *Lancet Neurol* 2019; **18**(7): 684-96.
129. Ballerini L, Booth T, Valdes Hernandez MDC, et al. Computational quantification of brain perivascular space morphologies: Associations with vascular risk factors and white matter hyperintensities. A study in the Lothian Birth Cohort 1936. *Neuroimage Clin* 2020; **25**: 102120.
130. Bouvy WH, Biessels GJ, Kuijf HJ, Kappelle LJ, Luijten PR, Zwanenburg JJ. Visualization of perivascular spaces and perforating arteries with 7 T magnetic resonance imaging. *Invest Radiol* 2014; **49**(5): 307-13.
131. Piantino J, Boespflug EL, Schwartz DL, et al. Characterization of MR Imaging-Visible Perivascular Spaces in the White Matter of Healthy Adolescents at 3T. *AJNR Am J Neuroradiol* 2020; **41**(11): 2139-45.
132. Adams HH, Cavalieri M, Verhaaren BF, et al. Rating method for dilated Virchow-Robin spaces on magnetic resonance imaging. *Stroke* 2013; **44**(6): 1732-5.
133. Gutierrez J, Elkind MS, Cheung K, Rundek T, Sacco RL, Wright CB. Pulsatile and steady components of blood pressure and subclinical cerebrovascular disease: the Northern Manhattan Study. *J Hypertens* 2015; **33**(10): 2115-22.
134. Paradise MB, Beaudoin MS, Dawes L, et al. Development and validation of a rating scale for perivascular spaces on 3T MRI. *J Neurol Sci* 2020; **409**: 116621.
135. Wang X, Valdes Hernandez Mdel C, Doubal F, et al. Development and initial evaluation of a semi-automatic approach to assess perivascular spaces on conventional magnetic resonance images. *J Neurosci Methods* 2016; **257**: 34-44.
136. Gonzalez-Castro V, Valdes Hernandez MDC, Chappell FM, Armitage PA, Makin S, Wardlaw JM. Reliability of an automatic classifier for brain enlarged perivascular spaces burden and comparison with human performance. *Clin Sci (Lond)* 2017; **131**(13): 1465-81.
137. Zhang J, Gao Y, Park SH, Zong X, Lin W, Shen D. Structured Learning for 3-D Perivascular Space Segmentation Using Vascular Features. *IEEE Trans Biomed Eng* 2017; **64**(12): 2803-12.
138. Ballerini L, Lovreglio R, Valdes Hernandez MDC, et al. Perivascular Spaces Segmentation in Brain MRI Using Optimal 3D Filtering. *Sci Rep* 2018; **8**(1): 2132.
139. Boespflug EL, Schwartz DL, Lahna D, et al. MR Imaging-based Multimodal Autoidentification of Perivascular Spaces (mMAPS): Automated Morphologic Segmentation of Enlarged Perivascular Spaces at Clinical Field Strength. *Radiology* 2018; **286**(2): 632-42.
140. Schwartz DL, Boespflug EL, Lahna DL, Pollock J, Roesse NE, Silbert LC. Autoidentification of perivascular spaces in white matter using clinical field strength T1 and FLAIR MR imaging. *Neuroimage* 2019; **202**: 116126.
141. Sepehrband F, Barisano G, Sheikh-Bahaei N, et al. Image processing approaches to enhance perivascular space visibility and quantification using MRI. *Sci Rep* 2019; **9**(1): 12351.
142. Boutinaud P, Tsuchida A, Laurent A, et al. 3D Segmentation of Perivascular Spaces on T1-Weighted 3 Tesla MR Images With a Convolutional Autoencoder and a U-Shaped Neural Network. *Front Neuroinform* 2021; **15**: 641600.
143. Dubost F, Adams H, Yilmaz P, et al. Weakly supervised object detection with 2D and 3D regression neural networks. *Med Image Anal* 2020; **65**: 101767.
144. Dubost F, Yilmaz P, Adams H, et al. Enlarged perivascular spaces in brain MRI: Automated quantification in four regions. *Neuroimage* 2019; **185**: 534-44.

145. Jung E, Chikontwe P, Zong X, Lin W, Shen D, Park SH. Enhancement of Perivascular Spaces Using Densely Connected Deep Convolutional Neural Network. *IEEE Access* 2019; **7**: 18382-91.
146. Lian C, Zhang J, Liu M, et al. Multi-channel multi-scale fully convolutional network for 3D perivascular spaces segmentation in 7T MR images. *Med Image Anal* 2018; **46**: 106-17.
147. Sleight E, Stringer MS, Marshall I, Wardlaw JM, Thrippleton MJ. Cerebrovascular Reactivity Measurement Using Magnetic Resonance Imaging: A Systematic Review. *Front Physiol* 2021; **12**: 643468.
148. Wahlin A, Eklund A, Malm J. 4D flow MRI hemodynamic biomarkers for cerebrovascular diseases. *J Intern Med* 2022; **291**(2): 115-27.
149. Shi Y, Thrippleton MJ, Marshall I, Wardlaw JM. Intracranial pulsatility in patients with cerebral small vessel disease: a systematic review. *Clin Sci (Lond)* 2018; **132**(1): 157-71.
150. van den Brink H, Kopczak A, Arts T, et al. CADASIL Affects Multiple Aspects of Cerebral Small Vessel Function on 7T-MRI. *Ann Neurol* 2022.
151. Geurts LJ, Zwanenburg JJM, Klijn CJM, Luijten PR, Biessels GJ. Higher Pulsatility in Cerebral Perforating Arteries in Patients With Small Vessel Disease Related Stroke, a 7T MRI Study. *Stroke* 2018: STROKEAHA118022516.
152. Arts T, Siero JCW, Biessels GJ, Zwanenburg JJM. Automated Assessment of Cerebral Arterial Perforator Function on 7T MRI. *J Magn Reson Imaging* 2021; **53**(1): 234-41.
153. Geurts L, Biessels GJ, Luijten P, Zwanenburg J. Better and faster velocity pulsatility assessment in cerebral white matter perforating arteries with 7T quantitative flow MRI through improved slice profile, acquisition scheme, and postprocessing. *Magn Reson Med* 2018; **79**(3): 1473-82.
154. Thrippleton MJ, Backes WH, Sourbron S, et al. Quantifying blood-brain barrier leakage in small vessel disease: Review and consensus recommendations. *Alzheimers Dement* 2019; **15**(6): 840-58.
155. Shao X, Ma SJ, Casey M, D'Orazio L, Ringman JM, Wang DJJ. Mapping water exchange across the blood-brain barrier using 3D diffusion-prepared arterial spin labeled perfusion MRI. *Magn Reson Med* 2019; **81**(5): 3065-79.
156. Dickie BR, Parker GJM, Parkes LM. Measuring water exchange across the blood-brain barrier using MRI. *Prog Nucl Magn Reson Spectrosc* 2020; **116**: 19-39.
157. Paech D, Radbruch A. Dynamic Glucose-Enhanced MR Imaging. *Magn Reson Imaging Clin N Am* 2021; **29**(1): 77-81.
158. Xu X, Yadav NN, Knutsson L, et al. Dynamic Glucose-Enhanced (DGE) MRI: Translation to Human Scanning and First Results in Glioma Patients. *Tomography* 2015; **1**(2): 105-14.

## Supplemental panels

### Supplemental panel 1: List of non-recommended terms

#### Recent small subcortical infarct

- Lacune
- Lacunar infarct
- Acute lacune

#### Lacune (of presumed vascular origin)

- Lacunar infarct
- Silent stroke
- Silent infarct
- Covert lacunar infarct

#### White matter hyperintensity (of presumed vascular origin)

- Ischaemic leukoaraiosis
- Ischaemic white matter hyperintensities
- White matter lesion

#### Perivascular space

- Enlarged perivascular space

#### Cerebral microbleed

- Microhaemorrhage

#### Cortical superficial siderosis

- Haemosiderosis

#### Brain atrophy

- Brain shrinkage

#### Summary SVD score

- Total SVD score
- SVD burden

#### Cortical cerebral microinfarct

- Cerebral microinfarcts
- Chronic microinfarcts

## **Supplemental panel 2: Terms for structural quantitative imaging markers of SVD brain damage**

### Preferred terms:

- Diffusion tensor imaging (DTI): quantification method and not a data acquisition scheme
- Mean diffusivity: marker of hindered / Gaussian diffusion
- Free water: (apparent) free water. In analogy to the apparent diffusion coefficient.
- Compartmental fractions derived from DWI models, free water: signal fraction and not volume fraction (unless corrected with a calibrated T2 value)
- R2\*: data acquisition of iron content with a gradient echo
- QSM: quantification method of susceptibility

### Terms to avoid:

- Mean diffusivity: cellular/parenchymal diffusion (due to sensitivity to other partial volume effects that might confound the biological interpretation)
- All DTI-derived metrics: axonal integrity, myelin integrity/demyelination, ultrastructural changes
- Free water: extracellular water, oedema, inflammation
- QSM: is not an acquisition technique

### Supplemental panel 3: Proposed reporting standards for neuroimaging studies of small vessel disease

#### Details of the research participants and reference population

- Age, sex, and main inclusion/exclusion criteria for the study.
- Proportions of individuals with vascular risk factors and how these were measured.
- Proportions of individuals with stroke and its subtypes, as well as other clinically diagnosed vascular comorbidities.
- Proportions of individuals with cognitive impairment and its likely aetiology according to accepted consensus criteria.
- Time from disease presentation to imaging and clinical assessments (if relevant).
- Any clinical or imaging observational period with time intervals.
- For studies on cognition or specific physical functions: details of test versions used, who administered them, and their training.
- For cognitive studies: assessment of premorbid cognitive ability including education, and depression.

#### Image acquisition

- Scanner characteristics (type and manufacturer, field strength, software version, coils, and wherever relevant also consider reporting on use of high-order shim and shimming routines, quality assurance protocol for scanner and frequency of quality assurance assessment).
- Change of scanners or change to scanner system during study.
- MRI sequences, acquisition parameters (including as appropriate: repetition time, echo time, inversion time, echo train length), acquisition and reconstruction matrices, field-of-view, slice thickness including gaps and scanning plane, details of selected options (tailored excitation pulses, parallel imaging, flow compensation, preparation pulses, etc), and total acquisition time.
- Crucial sequence-specific details, e.g., for diffusion MRI: b-values, number of diffusion directions, use of multiband imaging.
- If a work-in-progress/in-development software package or MRI acquisition sequence is used, provide as much information as possible.

#### Image analysis and postprocessing

- Characteristics of analysis software application (manufacturer, software version, image data format used for processing, and computer platform).
- Expertise of those performing the analyses (or oversight of an expert); see below
- Use and qualification of a central analysis facility, or training procedure across several analysis centres.
- Disclose whether analyses were done blinded to initial presentation or to other data (should be specified) that might influence interpretation.
- Details of qualitative visual rating and quantitative computational methods, including the URL if available for download or an appendix describing the method in detail, including its validation.
- For visual ratings: whether images were rated centrally by one or more readers; the raters' background (e.g., neurology, psychiatry, neuroradiology, or radiology) and experience; rater reliability (intra-rater and inter-rater).
- For all studies, whether using visual assessments or computational image analysis programmes: training of the analysts, any expert supervision, and the background of the expert.
- Repeatability (scan-rescan) and reproducibility (inter-scanner) of the method.
- Statistical methods used in data analysis.
- Ideally, include power analysis information on sample size estimates.

### Small vessel disease-specific aspects

- For **recent small subcortical infarcts**: specify whether infarcts are symptomatic or not; state the location, size, shape, and number; specify the delay from stroke to imaging; state the proportion with visible acute lesion on diffusion-weighted imaging and fluid-attenuated inversion recovery, plus T2-weighted imaging, or visible on CT if appropriate.
- For **lacunes (of presumed vascular origin)**: specify location, size, shape, and number; identify any haemorrhagic features; for volumetric methods, state whether lacunes are counted as part of CSF volume, as part of the white matter hyperintensity volume, or as separate lacune volume.
- For **white matter hyperintensities (of presumed vascular origin)**: specify the sequence used; specify whether deep grey matter and brainstem hyperintensities are included (and if so, refer to all hyperintensities collectively); state the rating scale or volume measurement software used, the reference or URL (if available) and observer reliability; specify whether the white matter hyperintensity volume was adjusted for intracranial or brain volume and how this was done; state whether lacunes were included in white matter hyperintensities or measured separately and whether acute lesions were masked.
- For **perivascular spaces**: separate perivascular spaces of the basal ganglia and white matter, and where available hippocampus and brainstem; describe how qualitative aspects (number, location, size, etc) are defined; state the observer reliability of the rating scale; for computational assessments, give full details of the software (URL where available), its validation, reproducibility, and the PVS parameters that are measured.
- For **cerebral microbleeds**: specify number and distribution divided into lobar, deep, and infratentorial (brainstem and cerebellum - the latter subdivided into deep and lobar); specify the sequence used; specify application of standardised rating scales. For computational assessments, give full details of the software (reference or URL where available), its validation, reproducibility, and the CMB parameters that are measured.
- For **cortical superficial siderosis**: state whether it is focal (involving  $\leq 3$  sulci) or disseminated (involving  $>3$  sulci); state the scale used, its validation and repeatability, or similar details of any computational method used.
- For brain **atrophy**: specify the rating scale or method of volume measurement, whether corrected for intracranial volume, and method used to do this.
- For **summary SVD score**: we recommend reference to a validated score, noting any adaptation made, utilising reporting standards for each SVD included in the score. New scores will be developed and require careful validation and testing in diverse populations.
- For (old) cortical **cerebral microinfarcts**: the sequence used; the number, location, size; details of the assessment method, its reproducibility and whether validated externally; expertise of raters; details of computational assessment method.
- For **structural quantitative markers of SVD brain damage**: report processing pipeline and software used, avoid assumptions of underlying aetiology/pathology and report measures/values as derived from the acquisition method or post-processing.
- For **markers of cerebrovascular function**: report processing pipeline and software used, whether validated externally; its repeatability; tissues from which values were extracted and how these were delineated (ROI, voxel-based); methods used to reduce contamination of the tissue signal by vessels or other tissues.



## **Supplemental panel 4: Questions to be addressed in future imaging studies of small vessel disease**

### **Recent small subcortical infarct**

- Factors determining long term fate of the lesion itself and secondary features (secondary tract changes, cortical changes).
- Relationship of RSSI appearance to the likelihood of underlying intrinsic versus non-intrinsic aetiology (e.g., intra- or extracranial atheroma, or cardioembolic).
- Relationship of RSSI long term fate (of the lesion itself and secondary features) to functional, cognitive and neurobehavioural outcomes.

### **Lacune (of presumed vascular origin)**

- Can lacunes truly disappear from imaging? If so, what are the associated factors?
- Can we improve the differentiation of lacunes from perivascular spaces?
- Does lacune aetiology differ by brain location?
- Is computational detection and assessment of lacunes feasible or reliable?

### **White matter hyperintensity (of presumed vascular origin)**

- Is there a 'normal' WMH volume or score for age?
- Set minimum standards for WMH volume software accuracy with large practice datasets representative of a full range of feature and co-feature variation.
- Does WMH appearance vary with pathological stage (early, permanent)?
- Can reversible WMH be differentiated from permanent WMH?
- Identify factors influencing WMH regression vs progression.
- Does WMH aetiology differ by brain location and/or pattern (e.g., periventricular, multi-spot, peri-basal ganglia, posterior/confluent)?

### **Perivascular space**

- Do PVS predate development of other SVD lesions?
- Do PVS independently predict future cognitive decline?
- Is involvement of particular brain regions in increasing PVS an indicator of particular disease processes?
- Do PVS reflect impaired fluid flow?
- Are PVS clinically relevant?

### **Cerebral microbleed**

- Development of (semi)-automated methods for detection and mapping of CMB.
- Building large prospective studies assessing CMB accrual and precise location, with functional and cognitive outcomes.
- RCT integrating CMB assessment: (1) on pre-randomisation MRI to assess possible modification of the treatment effect and (2) during follow-up to see if CMBs are a surrogate for later clinical outcomes.

### **Cortical superficial siderosis**

- Development of (semi)-automated methods for detection and mapping of cSS.
- Building large prospective studies assessing cSS accrual and precise location, with the risk of future cerebrovascular events as well as with functional and cognitive outcomes.
- RCT integrating cSS assessment: (1) on pre-randomisation MRI to assess possible modification of the treatment effect and (2) during follow-up to see if cSS is a surrogate for later clinical outcomes.

### **Brain atrophy**

- Set minimum standards for computational methods for determining brain atrophy to reduce variation between methods and streamline quality assurance.
- Are some regional or global patterns of brain atrophy specific to SVD including particular SVD feature types or severities?

### **Summary SVD score**

- How can we create a validation matrix for future summary SVD scores that incorporate new imaging markers?
- How can we validate summary SVD scores that incorporate automated measures of SVD imaging features?
- How can we develop a summary SVD score for progression of SVD?
- How do we incorporate non-imaging SVD metrics, such as functional, cognitive, genetic, and blood biomarkers, into future multi-variable summary scores?

### **(Old) cortical cerebral microinfarct**

- Development of (semi)-automated methods for detection and mapping of old/chronic/persistent cortical CMI.
- What is the maximum size that can be considered as a CMI in acute to long term stages?
- What is the aetiology of cortical CMI – are they due to intrinsic SVD or extracerebral (e.g., embolic) causes?
- What is the optimal method (sequence) to detect CMI outside the cortical grey matter?

### **Incident DWI-positive lesion**

- Determine why some lesions are asymptomatic whereas others cause acute stroke-like symptoms.
- Determine the aetiology and pathology of DWI+ lesions.
- Determine the clinical relevance of DWI+ lesions.

### **Structural quantitative imaging markers of SVD brain damage**

- What is the specificity of quantitative imaging markers in SVD?
- Is there a meaningful role for quantitative imaging markers as clinical biomarkers?
- Can we provide a “standardised operational procedure” for the (automated) analysis of quantitative imaging markers?
- Provide histopathological validation of quantitative imaging markers.


### **Markers of cerebrovascular function in SVD**

- Establish which aspects of vascular function are abnormal in SVD.
- Establish to which extent abnormal vascular function precedes lesion formation.
- Establish risk factors and possible biological processes (e.g., to proteomics) for abnormal vascular function in SVD.


### **General**

- Define best practices for image analysis when applied to large datasets to help overcome sequence and scanner variation.
- What is the added value of structural or functional imaging biomarkers over conventional visible SVD features in relation to clinical expression or prognosis?
- Identify the extent of overlap of SVD features with features of other common neurodegenerative pathologies such as Alzheimer’s disease, including whether SVD features alter amyloid-PET or tau-PET tracer uptake, whether PET imaging helps differentiate the vascular from Alzheimer’s disease contribution to cognitive impairment in vivo, or predict future decline.


## Supplemental figures

**Supplemental figure 1: Adoption of STRIVE-1 terminology in the literature since 2014**


Publication frequency of STRIVE-1 terms over time. The STRIVE-1 terminologies are plotted in blue and compared with the most frequent alternative terms. Search terms described in the literature search strategy that yielded very low numbers were omitted from the figure for improved readability. The numbers are absolute number of papers found per year, based on the literature search strategy (page 5). Note one paper might contribute more than one term (e.g., if a paper uses in the title “lacune” and as key word “silent brain infarct” it would be counted towards each of these terms).



**Supplemental figure 2: CT perfusion time to drain maps.** Delayed perfusion in the left lenticular nucleus corresponding to a RSSI (Syngo.via CT neuroperfusion, Siemens Healthineers, Erlangen, Germany).




**Supplemental figure 3: Time series illustrating the evolution of two incidental DWI+ lesions into small cavities.** Two DWI+ lesions were identified in monthly MRI scanning (time point 0, arrow). While the DWI+ lesion fades, high-resolution (0.85 mm isotropic) 3D-FLAIR and 3D-T1-weighted (T1w) imaging show the development of small cavities (arrows), which are less than 3 mm in diameter and thus do not fulfil the criteria of a lacune (of presumed vascular origin). As expected, the cavities are barely visible on FLAIR and best seen on T1w images. All images were brain-extracted and registered with a longitudinal FLAIR template as reference. Data from the RUN DMC – InTENse high-frequency serial imaging study.<sup>9</sup>



**Supplemental figure 4: Time series illustrating the evolution of a recent small subcortical infarct.**

The CT in the subacute phase of stroke shows a new left thalamic RSSI (arrow). By time of the first MRI (2 months after the CT scan) the RSSI has fogged on FLAIR and T2-weighted images (T2w) but is visible on susceptibility-weighted imaging (SWI) as a small triangular T2\* hypointensity ('smudge') (arrow). The lesion then gradually reappears on FLAIR (arrow) and then T2w, while the SWI lesion gradually 'dissolves'.



**Supplemental figure 5: Time series illustrating the evolution of a recent small subcortical infarct.** The RSSI is just visible on subacute phase CT in the left thalamus (arrow). By time of the first MRI, the left thalamic RSSI has largely fogged. It then reappears as a lesion on FLAIR and T2-weighted (T2w) images (arrows).